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ABSTRACT

This dissertation contains three parts based on my
research project which investigates three aspects of rab
bit muscle phosphofructokinase (ATP : D-fructose-6-phosphate-1-phosphotransferase, EC 2.7.1,11; PFK).

The first

part reports the isolation and characterization of two
full-length rabbit muscle PFK cDNAs.

The DNA sequences

of these two cDNAs (cDNA-A and cDNA-B) show an identical
coding sequence but heterogeneous 5' untranslated
regions.

cDNA-A is formed by removal of a 1.7 Kb up

stream intron while cDNA-B retains the 3' region of this
intron.
The second part describes the expression of the cDNA
in several bacterial hosts.

Recombinant rabbit muscle

PFK has been expressed at a significant level in a PFK
deficient E. coll strain DF1020 using the plasmid pPL2 as
the expression vector.

This expression system provides a

visible selection for clones which express rabbit muscle
PFK.

The recombinant PFK resembles the enzyme purified

from rabbit muscle with respect to its affinity for
substrates, its allosteric behavior and its physical
properties.
The third part shows the structural and functional
role of Gln-200 in rabbit muscle PFK (RMPFK). The
comparison of the amino acid sequence of RMPFK to that of

xl

the PFK from Bacillus stearothermophilus suggests that
Gln-200 of RMPFK is located in a region corresponding to
the 6-F loop.

This loop plays a critical role in the R-T

transition of BsPFK.

Mutation of RMPFK at position 200

affects the apparent affinity of the enzyme for Fru 6-P
under the conditions for which RMPFK behaves
allosterically. Three mutations were made at position
200: Gln-200 -► Arg <Q200R), Gln-200
Gln-200 -* Ala (Q200A). The

SQ.5(Fru

Glu (Q200E), and
6-P) of the Q200R

mutant is 4-fold lower than that of the wild type RMPFK.
The S Q 5 jFru g_p) of the Q200E mutant is increased about
14-fold.

The Q200A mutant cannot achieve half

saturation, even at a concentration of Fru 6-P over 200
mM.

Sigmoidal kinetics with respect to Fru 6-P were

observed with Hill coefficients of 2.4, 1.9, and 1.0 for
the wild type RMPFK and the Q200R and Q2Q0E mutants, re
spectively.

The data demonstrate that Gln-200 is a

residue important for the cooperative binding of Fru 6-P
to RMPFK.

xll

CHAPTER ONE
INTRODUCTION

1.1.

Background

Phosphofructokinase (PFK) (ATP : D-fructose-6-P-l
phosphotransferase, EC 2.7.1.11) catalyzes the formation
of fructose 1,6-bisphosphate (Fru 1,6-P2> and ADP from
fructose 6-phosphate (Fru 6-P) and ATP (Figure 1).

This

constitutes a major regulatory step in the glycolytic
pathway.

The reaction catalyzed by PFK in muscle was

first discovered by Ostern et al. (1936).

Recognition of

the rate-limiting role of PFK in frog muscle was initially
made by Cori (1942).

Lardy and Parks (1956) found that

ATP is a potent inhibitor of partially-purified muscle
PFK.

ATP inhibition of PFK from rabbit tissues could be

relieved by Fru 6-P, Fru 1,6-P2
Lowry, 1963).

and AMP (Passonneau and

It was found that the Fru 6-P saturation

curve for most PFK isozymes from animal is sigmoidal (Pas
sonneau and Lowry, 1963).

This indicates the existence of

cooperative interactions between subunits, and reveals the
allosteric nature of this enzyme.

Negative effectors

decrease the affinity for Fru 6-P and positive effectors
increase the affinity for Fru 6-P.

Citrate, a metabolite

which enhances intracellular coordination of glycolytic

1
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and mitochondrial ATP production, is another potent
inhibitor of PFK (Garland and Randle, 1963; Parmeggiani
and Bowman,1963).

In the early-1980s fructose 2,6-

bisphosphate (Fru 2,6-P2)# an extremely potent activator
of PFK, was discovered by several research groups (Pilkis
et al., 1961; Uyeda et al., 1981; Van Schaftingen et al.,
1960) . At low concentrations, 1 to 10 liM, this sugar
bisphosphate can relieve ATP and citrate inhibition while
increasing Fru-6-P affinity for various isozymes of mamma
lian PFK (Uyeda et al., 1981; Van Schaftingen et al.,
1980a).
Numerous isozymes of PFK have been isolated from
various animal tissues.

In rabbits, three distinct PFK

subunit types have been isolated and analyzed by
polyacrylamide gel electrophoresis in the presence of
sodium dodecyl sulfate (SDS-PAGE) (Foe and Kemp, 1984,
1985).

These three types of subunit have been classified

as M (muscle type), L (liver type) and C (brain type)
(Tsai and Kemp, 1974; Thrasher et al., 1981).
unit has a molecular mass of 85000 ± 5000.

Each sub

A tetramer of

these subunits is apparently the smallest active aggregate
(Reinhart and Lardy, 1960).

The relative abundances of

these different PFK subunits in different tissues leads to
the formation of tissue-specific patterns of homo- and
heterotetrameric enzymes, which show different

4

immunochemical, chromatographic and regulatory properties
(Dunaway, 1903; Foe and Kemp, 1985).
The kinetic properties and the physiological
relevance of mammalian PFK isozymes have been subjects of
intense research over the past 60 years.

However, the

knowledge of the structural properties of these PFK
isozymes was obscure until the report of the amino acid
sequence of rabbit muscle PFK (RMPFK) (Poorman et al.,
1904), which provided a breakthrough in PFK research.
Based on the information of the amino acid sequence of
this enzyme, our laboratory was able to clone the RMPFK
gene and to study its structure (Lee et al., 1987).

Amino

acid sequence comparisons of RMPFK with the prokaryotic
enzyme indicate that the mammalian PFK probably evolved by
duplication of and divergence from the prokaryotic gene
(Poorman et al., 1984).

Furthermore, possible substrate

and effector sites in RMPFK have been assigned based on
the crystallographic structure of bacterial PFK and a
comparative sequence analysis (Poorman et al., 1984;
Hellinga and Evans, 1985).

This putative structural model

of RMPFK provided us a hypothetical basis for investigat
ing the relationships of structure and function within the
RMPFK enzyme.

The accumulation of technological know-how

together with the availability of DNA fragments of the
RMPFK gene allowed us to clone and characterize the full
length cDNA of RMPFK.

This accomplishment opens two

5

fronts of PFK research to us: first, the characterization
of the promoter region of the RMPFK gene and second, the
investigation of the relationships between structure and
function within this complex enzyme.
This dissertation consists of three parts.

The

first part presents the cloning and characterization of
the full length cDNAs of RMPFK; the second part, the ex
pression of cloned RMPFK cDNA in E. coli and the
purification and characterization of the recombinant PFK;
and the third part, the investigation of the allosteric
properties of this enzyme by site-directed mutagenesis.

1.2.

Studies on the Reaction Mechanism of PFK

Studies of the reaction mechanism of PFK are
complicated by the fact that the PFK activity is influ
enced allosterically by the concentrations of MgATP, Fru+2
xo
6-P and free Mg . The influence of Mg
can be minimized
by using it in excess and treating the reaction as a twosubstrate system (Uyeda, 1970).

The substrates and prod

ucts may exert regulatory effect as well as catalytic ef
fects.

Since mammalian PFK generally loses its suscepti

bility to regulation as the pH becomes more alkaline
(Uyeda, 1970; Uyeda, 1972; Hanson et al., 1973; Bloxham
and Lardy, 1973),

kinetic measurements are typically per

formed above pH 8.0.
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Uyeda (1972) reported evidence that the reaction
mechanism of RMPFK is a sequential ordered mechanism.
Hanson et al. (1973), however, suggested the mechanism of
RMPFK is a sequential random mechanism.

Brand and Soling

(1973) reported evidence that the mechanism of rat liver
is sequential ordered.
The crucial factor in determining whether the reac
tion mechanism of PFK is either sequential random or or
dered is the product inhibition pattern of Fru 1,6-P2 with
respect to Fru 6-P.

The major difficulties with Fru 1,6-

P2 are that it has multiple binding sites on the enzyme,
and it is also a potent allosteric activator of the en
zyme.

These factors plus other factors, such as free and
J.O

bound Mg * concentration, affects PFK activity, which
makes kinetic studies of reaction mechanism extremely dif
ficult (Uyeda, 1979).
There is limited information about the reaction
mechanism of bacterial PFK.

Spaico and Anderson (1969)

reported that the reaction mechanism of Aerobacter
aerogenes is a sequential ordered mechanism.

The studies

on reaction mechanism of PFK from Lactobacillus easel and
Lactobacillus plantrum also demonstrated that these en
zymes exhibit sequential and ordered mechanism (Doelle,
1972).

The binding of Fru-6-P and ATP to the minor E.

coll PFK (PFK-2) is also sequential and ordered (Kotlarz

and Buc, 1981).

Deville-Bonne et al. (1991) reported that

the reaction mechanism of the major E. coli PFK (PFK-1)
resembles that of muscle PFK (Hanson et al., 1973), and
corresponds to a sequential mechanism for a random bireac
tant system in rapid equilibrium (Segel, 1975; Cleland,
1990).

1.3.

Mechanisms of Cooporativity and Allostarie
regulation in PFK

1.3.1.

Properties and mechanisms of allosteric
enxymes

Allosteric proteins control and coordinate chemical
events in the living cell.

By virtue of indirect interac

tions between distinct binding sites mediated by the pro
tein molecule, a protein's activity may be regulated by
ligands dissimilar to its own substrate.

The term homo

tropic is used to denote the interactions among the iden
tical substrate molecules, whereas the term heterotropic
is used for the interactions of the allosteric effectors
with substrates.

A sigmoidal saturation curve is observed

for the activity profile of an allosteric enzyme.

The ef

fect of the sigmoidal type of response is that the sub
strate will tend to be held within more narrow confines of
concentration.
Classical models of protein cooperativity are based
on the concept of multiple equilibria between several
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conformational states,

ranging from a T state with low af

finity to an R state with high affinity
activators.

for substrates and

The "concerted-symmetry" model of Monod,

Hyman, and Changeux (MWC model) predicts that the oligo
meric enzyme can exist

in either of two forms, T or R

(Monod et al., 1965),

In the transition between them, the

symmetry of the molecule would be conserved, so that the
activity of all its subunits would be either equally low
or equally high.

This assumption allowed the formulation

of a mathematical model with only three independent vari
ables: Kt and Kr, the dissociation constants of the ligand
with the protein in the T- and the R-structures, and Lo =
[T]/ [R], the concentration ratio of the two structures in
the absence of ligand.

In homotropic allosteric activa

tion, a substrate molecule may bind only to the more ac
tive form (R form) of the enzyme.

Thus, increasing the

substrate concentration not only increases the fraction of
substrate-bound enzyme form, but also shifts more of the
enzyme into a more active form with all subunits in the R
conformation.

These effects lead to the increase in the

rate of reaction.

Effector alters the To/Ro ratio by

preferentially stabilizing one of the forms.
bind preferentially to the R state.
by binding to the T state.

Activators

Inhibitors function

The simplicity of this model

provides a easy way to analyze data and explain phenomena.
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The "sequential" model of Koshland, Nemethy, and
Filmer (KNF model) is similar to the MWC model, but it al
lows the two conformations of subunits to coexist within
one oligomeric enzyme (Koshland et al., 1966).

It assumes

that the progress from the T to the ligand-bound R state
is a sequential process.

The conformation of each subunit

changes in turn as it binds the ligand, and there is no
dramatic switch from one state to another.

The number of

constants required is equal to the number of binding
sites, unlike the situation in the MWC model, which always
uses three.

1.3.2.

Regulatory mechanism of bacterial PFKs

PFK from E, coli is a tetramer of 4 identical sub
units

that displays highly cooperative kinetics with re

spect to Fru-6-P and hyperbolic kinetics with respect to
ATP.

In addition, it is activated by ADP or GDP, and is

inhibited by phosphoenolpyruvate (PEP) (Blangy et al.,
1968).

PFK from B, stearothermophilus behaves similarly,

except that the kinetics with respect to Fru 6-P are sig
moidal only in the presence of PEP; that is, the lowaffinity state is only populated in the presence of PEP
(Valdez et al., 1989).

Structures of the high-affinity

form (R state) and the low-affinity form (T state) have
been well characterized for the enzymes from both species.
The homotropic cooperativity with respect to Fru 6-P will

10

be discussed in Section 1.4 in connection with the details
of the crystal structures of the bacterial PFKs.
The steady-state kinetics of E. coli PFK were stud
ied by Blangy et ai. (1968) and were among the first en
zyme kinetics shown to fit to the MWC model of
cooperativity (Monod et al., 1965).

The R and T states of

PFK had the same affinity for ATP, but the apparent affin
ity for Fru 6-P of the R state was 2000 times higher than
that of the T state (Table 1).

In the absence of ligand,

PFK was mainly in the T state with the fraction of the
protein in the R state being less than 10-6 (Table 1).
These states did not have the same affinity for the allos
teric effectors: the activator ADP (or GDP) bound
preferentially to the R state, and the inhibitor PEP bound
to the T state.

Thus, the activators ADP and GDP

increased the affinity of PFK for Fru-6-P by favoring the
R state, while the inhibitor PEP decreased this affinity
by favoring the T state (Table 1).

Neither GDP nor PEP

altered the maximum rate of the reaction (Blangy et al.,
1968; Blangy 1971).
Some recent results have suggested, however, that a
unique structural transition between the two states R and
T of E. coli PFK could not account for both the homotropic
allosteric effects and the heterotropic effects at the
same time.

First, the three-dimensional structure of un-

liganded PFK resembled that of the R state (Rypniewsky and

11

Table 1
Thermodynaala paraaaters of X. coli PFK

Ligand

ATP
Fru-6-P
ADP

Kr (M)

kt

<M)

6 x 10-5

6 x 1CT5

1.25 x ItT5

2.5 x 10"2

2.5 x 10"5

1.3 x 10~3

GDP

4 x 10"5

>4 x 10“2

PEP

>7.5 x 10"1

7.5 x 10"4

Kr : dissociation constant of ligand in the R conformation
Kt : dissociation constant of ligand in the T conformation
N * 4 (number of protomers)
Lo ■ 1 x 10® (the equilibrium constant between the T state
and R state in the absence of ligand)
c - KR(Fru-6-P) ^KT(F-6-P)
5 x
binding coefficient)
(Adapted from Blangy et al., 1968)

(non-exclusive
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Evans, 1989), whereas the concerted model predicted that
it should be in the T state-

Second, the three-

dimensional structures of the PFK from E. coli in the ab
sence of effector (Rypniewsky and Evans, 1989) was similar
to that from S. stearotbermophilus (Evans et al., 1981),
which is mostly in the R state since its saturation by Fru
6-P is hyperbolic (Valdez et al., 1989).

Third, some mu

tant PFKs had properties which were not easily accounted
for by the concerted model (Lau and Fersht, 1987; Pertz,
1989; Berger and Evans, 1990).

For example, the mutation

of a single residue in the effector site, Glu-187 to Ala,
led to PEP being an activator rather than an inhibitor
(Lau and Fersht, 1987).

With low concentrations of the

substrate Fru 6-P, the mutant enzyme was 100 times more
active than wild type enzyme at millimolar concentrations
of PEP.

According to the MWC model, PEP binds to the T

state of wild type enzyme.

But the effects of PEP on the

mutant were consistent with PEP binding to an R state.
The data were not consistent with the conventional MWC
model.
In addition to the information on the X-ray crystal
structures of E. coli PFK and the kinetic data of the mu
tant PFKs, the pH-dependence of the properties of E. coll
PFK suggested that part of the cooperativity observed in
saturation by Fru 6-P was of kinetic origin (Devilie-Bonne
et al., 1991).

The studies showed that the cooperativity

increases markedly with pH (in the range of pH 6.0 to pH
9.0), reaching a value of Hill coefficient of n * 5.5-6.0
at pH 9.0.

Finding a value of the cooperativity coeffi

cient larger than the number of substrate binding sites
indicated that slow conformational changes may occur in
PFK.

The authors suggested that the MWC model may not be

sufficient to describe the enzymatic properties of PFK.
More recently, Deville-Bonne and Garel (1992) have
directly measured the binding of both substrates to PFK by
equilibrium dialysis and by fluorescence changes to evalu
ate the binding and kinetic contributions to the overall
cooperativity observed for the saturation of E. coli PFK
by Fru 6-P.

Their studies demonstrated that the equilib

rium data about ligand binding and conformational changes
were consistent with a transition between two states, a
low-fluorescence R state which bound the substrate Fru 6-P
and the activator ADP and a high-fluorescence T state
which bound the other substrate ATP and the inhibitor PEP,
with a To/Ro around 2 for free PFK.

These results are

quite different from those described earlier for PFK from
steady-state measurements (Blangy, 1968); the ratio
between the two states, To/Ro, was around 4 X 10® for free
PFK, and the the R and T states had the same apparent af
finity for the other substrate, ATP.

This major discrep

ancy between thermodynamic and kinetic data suggested that
contributions from both binding and catalysis are involved
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in allosteric control of activity (Deville-Bonne and
Garel, 1992).

1.3.3.

Regulatory properties of mammalian PFK

The major features of the regulation of mammalian
PFK are as follows:
a) .

Inhibition of the enzyme

by high concentrations of

ATP.

Generally, ATP decreases

itsaffinity for Fru 6-P.

b).

Inhibition by citrate.

tic with that of
c).

This inhibition is synergis

ATP.

Relief of the ATP inhibition by Pi, AMP, cAMP, ADP,

Fru 6-P, Fru 1,6-P2 and Fru 2,6-P2*
d).

Cooperativity of Fru 6-P binding.

Negative effec

tors decrease the affinity of PFK for Fru 6-P and positive
effectors increase the affinity for Fru 6-P.
These four features represent the principal regula
tory characteristics of various PFKs from mammalian
sources.

Their influence on the catalytic activity of PFK

is such that changes in concentrations of the effectors
occurring under physiological conditions enhance or re
press PFK activity in accord with the physiological need
for glycolytic intermediates and ATP.
Mammalian PFK exists as a pool of homo- or heterotetramers.

The tissue-specific expression of various

tetramers of PFK will be described in Section 1.4.

The

inhibitory action of ATP on RMPFK was first reported by
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Lardy and Parks in 1956.

Increasing the concentration of

ATP above that necessary for the optimum catalytic activi
ty caused a progressive decrease in PFK activity. Mansour
and Ahlfors (I960) showed that the inhibitory action of
ATP is reduced as the concentration of Fru 6-P increased.
The physiological significance of this inhibition phenome
non is obvious, since glycolysis serves to generate ATP in
anaerobic cells and also provides oxidizable metabolites
for mitochondria and aerobic cells.

Moreover, the fact

that the degradative products of ATP (i.e., AMP, ADP and
Pi) relieve ATP inhibition further supports the importance
of regulation of PFK activity by the energy status of a
cell.

Sensitivity to the ATP inhibition differs signifi

cantly in relation to the source of PFK.

The liver PFK is

most strongly inhibited by ATP, the brain enzyme is less
sensitive, and the muscle isozyme is least sensitive (Foe
and Kemp, 1983).
The pH of the medium plays an important role in the
ATP inhibition of PFK.

Hanson et al.(1973) reported that

RMPFK is inhibited by ATP and shows sigmoidal kinetics
behavior with respect to Fru 6-P at pH 7.0 and saturating
ATP concentration.

However, inhibition by ATP and cooper

ativity in Fru 6-P kinetics of this enzyme are not present
at pH 8.0.

Similar behavior is observed for PFKs from

brain (Lowry and Passonneau, 1966; Tsai and Kemp, 1974)
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diaphragm (Ui, 1966) , heart (Mansour and Ahlfors, 1968) ,
liver (Kemp, 1971), and placenta (Kahn et al., 1979).
The second major inhibitor of mammalian PFK is
citrate.

Citrate binds to the inactive form of PFK and

acts synergistically with ATP to displace the equilibrium
away from the R-state.

This reveals the link between gly

colysis and TCA cycle (Garland et al., 1963; Tsai and
Kemp, 1974),

Phosphocreatine, 3-phosphoglycerate, 2-phos-

phoglycerate, 2,3-bisphosphoglycerate are all inhibitors
of eukaryotic PFKs (Bloxham and Lardy, 1973; Uyeda, 1979).
The inhibition by these phosphorylated intermediates of
glycolysis is most pronounced below neutral pH and in the
presence of inhibitory concentrations of ATP (Colombo et
al., 1975).

On the other hand, AMP, cAMP, ADP, Pi, Fru 6-

P, Fru 1,6-P2 and Fru 2,6-P2 relieve or counteract the in
hibition of PFKs by ATP and negative effectors (Uyeda,
1979; Pilkis et al., 1981).
The physiological activity of some mammalian PFK is
sensitive to hormonal changes.

The ability of glucagon to

inhibit liver PFK was observed by Taunton and his
coworkers (1974).

Exton (1970) demonstrated that the

short-term effect of insulin in the liver is to counteract
the action of a small dose of glucagon.

Early studies

suggested that these hormones probably affect the cAMP-mediated phosphorylation of PFK (Taunton et al., 1974; Brand
and Soling, 1973).

Cyclic AMP-dependent protein
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kinase-catalyzed phosphorylation at a seryl residue in the
C-terminal region of skeletal muscle PFK has been reported
by Riguelme, et al. (1978).

However the regulatory

properties of the phosphorylated PFK are not much differ
ent from those of the dephosphorylated enzyme (Foe and
Kemp, 1982).

The physiological relevance of phosphoryla

tion of glycolytic and gluconeogenic enzymes has been
reviewed by Pilkis and his colleagues (1988).
The discovery of Fru 2,6-P2 provided a clear
explanation for the physiological regulation of PFK.

Fru

2.6-P2 has the ability to stimulate all mammalian PFKs
that have been tested (Van Schaftingen, 1980a, 19B0b;
Uyeda, 1981; Pilkis, 1981), including those extracted from
cells, such as erythrocytes, that do not contain fructose
2.6-bisphosphate.

The main characteristics of this stimu

lator were first described for the liver enzyme (Uyeda, et
al, 1981; Van Schaftingen et al., 1981a). It acts
synergistically with AMP to oppose the inhibitory action
of ATP and citrate (Pilkis, 1981; Uyeda, 1982; Claus,
1983).

It is well known that PFK is also stimulated by

Fru 1,6-P2 . For the liver enzyme, the concentration of
Fru 2,6-P2 needed to obtain a half-maximal stimulation is
1000 times lower than the concentration of Fru 1,6-P2 re
quired to reach the same effect (Van Schaftingen et al.,

1980a).

Studies by Foe et al. (1983) and by Kitajima and

Uyeda (1983) have shown that Fru 2,6-P2 binds to rabbit
muscle PFK with an approximately 10-fold higher affinity
than does Fru 1,6-P2 *

These two fructose bisphosphates

antagonize each other's binding.

This indicates that Fru

2,6-p2 and Fru 1,6-P2 probably bind to the same allosteric
site (Foe et al., 1983).
In rat skeletal muscle, insulin and epinephrine,
both

of which stimulate lactate production, have been

shown to increase the levels of Fru 2,6-P2 (Hue et al.,
1982; Bosca et al., 1985).

Bosca and co-workers (1985)

have proposed that the rise in Fru 2,6-p2 concentration
induced by epinephrine and insulin could enhance cycling
between Fru 6-P and Fru 1,6-P2 * PFK catalyzes the phos
phorylation of Fru 6-P to Fru 1,6-P2 in glycolysis.

On

the other hand, fructose 1,6-bisphosphatase catalyzes the
hydrolysis of Fru 1,6-P2 to give Fru 6-P and orthorphosphate during gluconeogenesis. Regulation at the 6-phosphofructo-1 kinase/fructo-1,6-bisphosphatase is now
thought to be mediated primarily by changes in the level
of Fru 2,6-P2 (Claus et al, 1984; Hue, 1987; Pilkis et
al., 1987).

In states where Fru 2,6-P2 levels are high,
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the activity of PFK and flux through the glycolytic
pathway are high, and fructose 1,6-bisphosphatase activity
is inhibited.

On the other hand, when Fru 2,6-p2 levels

are low, fructose 1,6-bisphosphatase activity is enhanced,
PFK activity is inhibited, and the gluconeogenic flux pre
dominates.

Fru 2,6-P2 can be thought of as a master

switching signal between gluconeogenesis and glycolysis.
Fru 2,6-P2 is formed by the phosphorylation of Fru
6-P, in a reaction catalyzed by 6-phosphofructo-2-kinase,
an enzyme distinct from 6-phosphofructo-l-kinase (PFK).
It is hydrolyzed to Fru 6-P by a specific phosphatase,
Fructose-2,6-bisphosphatase.

The level of Fru 2,6-P2 is

determined by the balance between the activities of 6phosphofructo-2-kinase and fructose-2,6-bisphosphatase.
It is indeed a striking finding that 6-phosphofructo-2-kinase and fructose-2,6-bisphosphatase activities are both
present within a single 53 KD polypeptide chain (ElMagharabi et al., 1962; Tauler et al., 1988).

This bi

functional enzyme is phosphorylated by the cAMP-dependent
protein kinase (Murray et al., 1984).

Phosphorylation of

a single seryl residue per enzyme subunit results in both
a decrease in kinase activity and an increase in
phosphatase activity (El-Maghrabi et al, 1982; Van Schaft
ingen et al., 1983, Kurland et al., 1992).
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In addition to the allosteric regulation by AMP/ATP,
citrate and Fru 2,6-P2f the synthesis of 6-phosphofructo1-Jcinase is also regulated at the level of transcription.
Mouse liver PFK mRNA synthesis has been shown to be under
hormonal, dietary and developmental control (Gehnrich et
al., 1988).

Gekakis et al (1989) have shown that both an

induction of mouse muscle PFK enzyme synthesis and an in
crease in mRNA concentration during myoblast differentia
tion.

1.3.4.

Molecular mechanism for the sigmoidal
kinetics of RMPFK

The molecular mechanism for the cooperative binding
of Fru 6-P by RMPFK is not fully understood.

Hill and

Hammes (1975) studied the binding isotherms of Fru 6-P and
Fru l,6-p2 at different pH's.

At pH 7.0, the binding iso

therms for Fru 6-P and Fru l,6-?2 exhibit negative
cooperativity; at this pH, PFK exists as a mixture of
dimers and tetramers.

At pH 8.0, the negative cooperativ

ity is less, and PFK is proposed to exist primarily as
tetramers.

At protein concentrations for which polymers

larger than the tetramer predominate, Fru 1,6-P2 binding

is hyperbolic.

Because the negative cooperativity of Fru

6-P binding to the enzyme is less in the tetramer than in

the dimer, there is a conversion of dimer to tetramer as
the enzyme is saturated with Fru 6-P.
The above binding studies were done in the absence
of ATP or its analogs.

In the presence of an ATP analog,

however, Fru 6-P binding is positively cooperative.

The

results fit a sequential mechanism (Koshland et al., 1966)
more closely than a two states mechanism (see below).
Such a mechanism explains the negative cooperativity more
adequately (Hill and Hammes, 1975).
Bock and Frieden (1976) offered an alternate expla
nation for the binding isotherm for Fru 6-P based on their
studies of the effect of pH on RMPFK.

Their studies

demonstrated that the degree of regulatory kinetic behav
ior of RMPFK increases with lower pH values at a given
temperature.

They postulated a model analogous to the

concerted model (Monod et al., 1965), in which two forms
of RMPFK exist, one protonated and the other not.

Fru 6-P

binds preferentially to the unprotonated form, while ATP
and citrate bind to the protonated form.

Thus, upon low

ering pH, regulatory behavior increases (Boch and Frieden,
1976; Frieden et al., 1976).
Because the experimental conditions, including pro
tein concentration and the presence or absence of ligands
are different for each study, it is difficult to correlate
the results of ligand binding and the resulting ligand-in
duced conformational changes with the kinetic properties.
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There Is no adequate model which can explain the mechanism
for the allosteric transition of RMPFK at this time.

1.4

Tissue Specificity of Mammalian PFK

The existence of multiple forms of PFK from various
mammalian tissues has been reported.

Animal PFK can exist

as a tetramer of molecular mass around 340,000.

Different

isozymes are present in different animal tissues.

They

result from the assembly of three types of subunits; M for
muscle type, L for liver and C for brain (Dunaway, 1983).
PFK isolated from muscle is a homotetramer of M-subunits,
whereas in liver and placenta, it is a mixture of tetram
ers with the L4-homotetramer as the major component.

In

fibroblasts, platelets and brain cells, PFK exist predomi
nantly as the C4-isozyme with other heterotetramers as
minor components.

The hybrid isozymes are distinguishable

from one another by the differences in their immunoprecipitation and kinetic properties (Dunaway, 1983; Foe and
Kemp, 1985).

In addition, the three subunit types can be

separated by SDS-polyacrylamide gel electrophoresis.
Several groups of investigators have been successful in
raising subunit-type specific antibodies (Dunaway, 1903).
Dunaway and co-workers (Dunaway et al., 1988) ana
lyzed various human tissues for PFK subunit composition,
and determined the kinetic and regulatory properties of
these PFK isozymes.

All three isozymes exhibited a

sigmoidal response to increasing concentration of Fru 6-P,
and a sensitivity to ATP inhibition.

However, the

isozymes are all kinetically distinct from one another.
The M4-homotetramer has the highest affinity for Fru 6-P.
Fru 2,6-P2 substantially enhances the affinity of the bl
and L- rich isozymes for Fru 6-P.

PFK composed solely of

C subunit, however, is much less sensitive to Fru 2,6-P2 .
Differences in kinetic and allosteric behavior of the var
ious tetramers allow tissue-specific regulation of PFK ac
tivity.

Thus, the rate of glycolysis is uniquely

controlled in muscle, liver and brain.

1,5.

Structure of PFK

1.5.1.

Sequence comparison of mammalian PFKs

The structural properties of PFK from eukaryotes are
as interesting and complex as its kinetic properties.

For

most mammalian PFKs, the molecular weight of the subunit
is approximately 85000 +. 5000.

The primary structures of

the rabbit muscle PFK (Poorman et al., 1984; Lee et a l .,
1987), the human muscle PFK (Nakajima et al., 1987), the
mouse liver PFK (Gehnrich et al., 1988), and the human
liver PFK (Levanon, 1989) have been determined either by
direct peptide sequencing, or by inference from the gene
or cDNA sequences (Fig. 2).

Gehnrich et al. (1988) re

ported that the amino acid sequence homology between the

rigura 2.
Comparison of ths amino acid saquancas of
human livar, mousa livar, and rabbit muscla PFK. Dashes
represent identity with the human liver PFK. Rabbit mus
cle (RMPFK) sequence is from Lee et al. (1987). Mouse
liver PFK (MLPFK) sequence is from Gehnrich (1988). Human
liver (HLPFK) sequence is from Levanon et al. (1989) .
(Adapted from Levanon et al.r 198 9)
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mouse liver PFK and the rabbit muscle PFK is 68%.

The

genes of the two muscle-type or of the two liver-type en
zymes from mouse and the rabbit have about 90% identity in
nucleotide sequences within the coding region.

However,

the degree of sequence similarity between the amino acid
sequences of human liver PFK and human muscle PFK is only
68% (Levanon et al., 1989) (Fig. 2).

Therefore, it ap

pears that the sequence of same type of PFK isozyme are
more conserved between mammalian species than among
isozymes in the same species.

1.5.2.

Sequence comparison of amino and carboxy
halves of BMPFK and those of bacterial PFK

Similarities in the amino acid sequences between the
PFK of B. stearothermophllus (BsPFK) and the amino and
carboxyl halves of rabbit muscle PFK (Figure 3) were no
ticed by Poorman et al. (1984).

The respective identities

for each comparison are 44% (BsPFK vs N-half), 34 % (BsPFK
vs C-half) and 32 % (N-half vs C-half). Therefore, they
have suggested that the mammalian PFK evolved from bacte
rial PFK by gene duplication and divergence.

This dupli

cation pattern is also observed in mouse liver PFK, human
liver PFK and even yeast PFK (Heinisch et al., 1989).
Based on this hypothetical evolutionary pathway and the
knowledge of the crystallographic structure of B,
stearothermophllus PFK (Kolb et al., 1980), a model
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explaining the tertiary structure and the function of
RMPFK has been proposed (Poorman et al., 1984) (Fig. 4).
The hypothetical tetramer of RMPFK shows the puta
tive catalytic and regulatory sites.

Residues involved in

these sites are located in the interface between subunits
or between the N- and C- halves of the same subunit.

The

roles of these amino acid residues have been proposed on
the basis of sequence homologies between bacterial PFK and
N- and C- halves of RMPFK (Poorman et al., 1984; Evans,
1985) (Table 2).

The N- half of RMPFK preserves most of

the critical catalytic residues found in bacterial enzymes
but some of the corresponding residues in the C- half are
not conserved.

In particular, this latter half has lost

the catalytic residue Asp-127, but preserved most of the
Fru-6-P binding residues, suggesting that the C- half has
lost its catalytic function and instead has become a
regulatory domain which binds Fru-2,6-P2 or other

effectors.

The effector site is less well conserved be

tween the bacterial and rabbit muscle enzymes, which is
consistent with their having different allosteric effec
tors.

1.5.3.

Three-dimensional structures of bacterial
PFK

The crystal structures of the PFK from
stearothermophllus

B.

and of the major PFK isozyme from

Figure 3.
The amino acid aaquancaa of the N- and Chalvas of rabbit muacla PFK (RMPFK) compared with thosa of
B. Stearothexmcphllu* PFK (BsPFK) and f. coil PFK-1 (Ic
PFK-t). Double-headed arrows (above all the sequences)
represent the secondary structure elements found In the
structure of B. Stearothermophllus enzyme. Numbers are
corresponding to the positions of residues in BsPFK. Un
derlined residues are those deduced from DNA sequence of
RMPFK gene (Modified from Hellinga and Evans, 1985).
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B
C-HALF, SUBUNIT 2

N- AND C-HALVES OF A SINGLE SUBUNIT

m

N-HALF, SUBUNIT t

Figure 4.
Location of substrata and affactor sitas in
BMPIK basad on crystallographic analysis of BsPFK and com
parative sequence analysis.
Residues enclosed in solid
boxes are identical to those at corresponding positions in
BsPFK; those enclosed in dotted boxes are different.
Numbers 1 and 2 represent the domains in a single subunit.
A. View along the z-dyad axis of the N- and C- halves of
the two adjacent subunits which together define sites for
cooperative binding of Fru-6-P (F6P) and fructose bisphosphates (FBP). Dotted lines between residues indicate pos
sible hydrogen bonds.
B. View along the x-dyad axis of
the halves of a single RMPFK subunit in which residues
presumed to be involved in binding ADP activator and ATP
inhibitor are noted.
The solid bar labeled 'connecting
peptide' represents the covalent bridge between the halves
related by the x-dyad axis. (Adapted from Poorman et al.,
1984) .
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A comparison of rasiduas in tha ligand binding sitas of
thraa ralatad PFKs: EcPrK-1 (Ec), BsPFK (Bs) , and tha Ntarminal and C-taxminal halvas of RMPFK [RM{N) and RM<C)] .
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Residue are listed under their number in the BsPFK
sequence.
Residues contributing to site A and C are di
vided between neighboring subunits in the tetramer. Resi
dues marked * are not in the subunit containing the main
part of the site.
The dyad symmetry axis relating the
subunit containing the main site are given as (p) or <r) .
(Adapted from Hellinga and Evans, 19B5)
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E. coli have been solved by Evans and his colleagues
(Evans and Hundson, 1979; Evans et al., 1986; Schirakihara
and Evans, 1988; Schirmer and Evans, 1989; Schlrmer and
Evans, 1990).

The molecular mechanism for the transition

between the R (Relaxed) and T (Tight)

conformations of

PFK is beginning to be understood from the recent results
of the crystal structure of BsPFK (Schirmer and Evans,
1989, 1990).

The R and T states of PFK differ primarily

in their quaternary structure: one pair of subunits in the
tetramer is rotated 7° with respect to the other pair of
subunits.

The restructuring of the 6-F loop is closely

correlated with the rotation of the dimers relative to
each other (Schirmer and Evans, 1990) (Fig. 5).
The binding site for the cooperative substrate Fru
6-P is altered by the change involving the 6-F loop
(Schirmer and Evans, 1990) (Fig. 6).

In the R state, a

major part of the binding energy comes from Arg-162 and
Arg-243 across the subunit interface (Fig. 6B). However,
Arg-162 swings around away from the active site in the T
state.

Glu-161, in turn, adopts the former (R state)

position of Arg-162 and forms a salt bridge with Arg-243
(Fig 6A). The positive charges of Arg-162 and Arg-243 are
no longer available for binding to the negatively charged
phosphate of Fru 6-P.

This in part accounts for the large

decrease in the affinity for Fru 6-P.

In E. coli PFK-1,
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•-F

R
T

Tigura 5.
G a n m l viav of BsPFK and its quaternary and
tertiary structure changes on the allosteric transition
from R to T. a. Schematic sketch of the R-state (dashed
outline) and Testate (solid outline) PFK tetramer, viewed
along r.
The three mutual perpendicular 2-fold symmetry
axes are labeled p, q and r. The subunits are labeled A0.
Residues labeled with * belong to subunit A, all
others to subunit D. b. R-state structure, subunit A and
D, related by r dyad as view as in a. Helices are repre
sented as cylinders numbered 1-13, 0-sheet strands are ar
rows labeled A-K. In the active site the substrate Fru-6P (F6P) and the product ADP are shown, in the effector
site the activator ADP is shown. (Schirmer and Evans,
1990)
(Reprinted by permission from Nature vol. 343,
pp.140-145; Copyright (c) 1990 Macmillan Magazines Limit
ed)
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Figure 6.
Schematic view of the 6-F loop (155-162) in
BsPFK showing its diffsrsnt intsrsctions scross the interfscs between dinars. The wavy line represents part of the
boundary between r-dyad-related subunits (that is, the
boundary between dimers). a. T-structure, showing Glu 161
in the Fru-6-P binding site, the Arg 72-Glu 241 salt
bridge. b. R-structure ( with bound ligands ADP and Fru6-P), showing the phosphate of Fru-6-P bound by Arg 162
and Arg 243.
(Schirmer and Evans, 1990) (Reprinted by
permission from Nature vol. 343, pp.140-145; Copyright (c)
1990 Macmillan Magazines Limited)
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residue 161 is Gin, so the charge change would be less
during the R to T transition.
Kinetic data have shown that Arg-162 and Arg-243 are
important residues in the T to R transition of E. coli
PFK-1 (Berger and Evans, 1990) . Residues 156-160, which
are located in the 6-F loop of E. coli PFK-1, also have
been shown to be critical in the T to R transition (Kundrot and Evans, 1991).

1.5.4.

Structural comparison of bacterial PFK and
rabbit muscle glycogen phosphorylase

High resolution refined structures are available for
the T and the R states for four allosteric proteins:
hemoglobin, E. coli aspartate transcarbamoylase, bacterial
PFK, and rabbit muscle glycogen phosphorylase.

In this

section, a structural comparison between bacterial PFK and
rabbit muscle glycogen phosphorylase was chosen because in
both bacterial PFK and rabbit muscle glycogen phosphory
lase, concerted movements of a basic group and an acidic
group create a phosphate recognition site (Johnson and
Barford, 1990).
Bacterial PFK and rabbit muscle glycogen phosphory
lase have very different subunit-subunit interfaces.
Furthermore, the types of secondary structures involved in
their subunit-subunit interfaces do not share any common
features (Johnson and Barford, 1990).

However, a
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structural comparison of these two allosteric proteins may
provide the information to understand how tertiary struc
tural changes associated with ligand binding closely
correlated with quaternary structural changes.
Glycogen phosphorylase (GP) catalyzes the degrada
tion of intracellular glycogen.
two identical subunits.

The enzyme is a dimer of

It exhibits homotropic effects

for binding of substrates and AMP, as well as heterotropic
effects (Black and Wang, 1968).

Comparison of the T and

the R structures of PFK and GP shows that the conforma
tional response at the ligand binding sites are small
(Johnson and Barford, 1990).

There are concerted move

ments of a basic group and an acidic group to create a
phosphate recognition site in both proteins (Arg-162 and
Glu-161 for PFK; Arg-569 and Asp-283 for GP) (Schirmer and
Evans, 1990; Barford and Johnson, 1989).
The mechanism for transmission of homotropic effects
is different between the two enzyme molecules.

In PFK the

substrate binding sites are at the subunit interface, and
changes in tertiary structure are directly involved in
quaternary changes at the subunit interface (Schirmer and
Evans, 1990).

In GP, however, tertiary structural changes

are not directly associated with the quaternary structural
changes (Johnson and Barford, 1990).

The substrate sites

are buried within the subunits, and ligand-induced changes
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in tertiary structure promote indirect long distance
changes at the interface (Barford and Johnson, 1989).
The locations of the effector sites involved in
heterotropic interactions also reveal differences between
these two enzymes.

In PFK, the regulatory sites are at a

rigid subunit interface and transmit a signal through
changes in tertiary structure to the substrate binding
site interface (Schirmer and Evans, 1990; Johnson and Bar
ford, 1990).

In GP, the regulatory sites are at subunit

interfaces (Barford and Johnson, 1989).

Structural stud

ies of the allosteric transitions of these two allosteric
enzymes provide the information to explain how two binding
sites located far away can communicate with each other.

1.6.

Rationale and Objective

1.6.1.

5' untranslated region of RMPIT gene

Mammalian PFK has three types of subunits which as
sociate to form different homotetrameric or heterotetrameric isozymes whose catalytic activities and regulation
properties are influenced by their composition (Dunaway,
1983; Foe and Kemp, 1985; Dunaway et al., 1988).

To

understand the tissue-specific abundances of these
isozymes, it is important to have a knowledge of the
structures of the different isozyme genes.

The gene

structure of RMPFK has been well studied by Lee et al
(1987), but the sequence in the promoter region of this
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gene has not been determined.

The isolation of the rabbit

muscle PFK cDNA reported here provides the sequence
downstream of the transcription initiation site in the 5'untranslated region of RMPFK gene.

This paves the way for

further characterization of the transcription start site
(sites) in the promoter region of this gene.

1.6.2.

Structure-function relationships of RMPFK

The kinetic properties and the physiological
relevance of mammalian PFK isozymes have been thoroughly
studied.

However, structure/function relationships for

these isozymes have not been elucidated.

The accomplish

ment of the expression of the cloned RMPFK in E. coll
cells should provide us with powerful tools to investigate
the structural/functional properties of muscle-type PFK
from a new perspective.

Crystallographic studies on BsPFK

have shown a switch between Arg-162 and Glu-161 at the
Fru-6-P binding site during the R-T transition (Schirmer
and Evans, 1990).

The allosterically inhibited BsPFK

shows subunit twisting that limits the access of Fru 6-P
to its binding site.

Sequence alignment of RMPFK with

BsPFK (Figure 3) suggests that Gln-200 and Arg-201 in
RMPFK are equivalent to Glu-161 and Arg-162 in BsPFK.

On

the basis of the crystal structure of BsPFK and the se
quence alignment between BsPFK and RMPFK, experiments were
designed to investigate the structural role of Gln-200 in

the R-T transition of RMPFK.

Mutation at Gln-200 may

either enhance or reduce the affinity for Fru-6-P binding
This mutation may also strengthen or weaken subunit inter
action,

in this study, Gln-200 has been mutated to

alanine, arginine, and glutamate to determine how the
charge and the size of the side chain at residue 200
affect the kinetic properties of this enzyme.

The specif

ic aims of this study are the following:
1. To clone the cDNA encoding rabbit muscle PFK.
2. To express the cloned RMPFK in an E. coli expression
system and to purify it.
3. To compare kinetic properties of authentic RMPFK and
cloned RMPFK.
4. To determine the structural and functional role of Gin
200 in the R-T transition of RMPFK by mutation of Gln-200
to alanine, arginine, asparagine and glutamic acid.

CHAPTER TWO
MATERIALS AND METHODS

2.1.

Materials

2.1.1.

Enzymes and antibody

Restriction endonucleases, DNA ligase, exo nuclease
III, mung bean nuclease, DNA kinase, T4 DNA polymerase were
purchased from Bethesda Research Laboratories (BRL)
(Bethesda,MD), Boehringer-Mannheim Biochemicals (Indianapo
lis, IN), New England Biolabs, Inc. (NEB) (Boverly,MA),
Promega Biotec Corporation (Madison, HI), and Pharmacia
(Piscataway, NJ). Nick translation kits and sequenase kits
were obtained from United States Biochemicals Corp. (USB)
(Cleveland, OH). Taq DNA polymerase kits were ordered from
Perkin Elmer Cetus (Norwalk, CT).

In vitro mutagenesis kit

was from Promega Biotec Corporation.

RNAse A, protein-A,

aldolase (Type IV), mixture of triose-phosphate isomerase
and glycerol 3-phosphate dehydrogenase (Type III) were pur
chased from Sigma Chemical Co. (St Louis, MO). Antiserum
against rabbit muscle phosphofructokinase was a gift from
Dr. Dunaway (Southern Illinois University).

2.1.2.

Chemicals

Bacto-tryptone, bacto-yeast extract, and bacto-agar
were purchased from Difco Laboratory (Detroit, MI).
Agarose, low melting point Seaplaque agarose, urea and
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phenol were obtained from BRL or American Research Products
Company (AMRESCO) (Solon, OH).

Acrylamide, N,N'-methylene-

bisacrylamide,, acrylamide stock solution (40 %, w/v) (ACRYL-40) and N,N'-methyllene-bis-acrylamide stock solution (2
%, w/v) (BIS-2) were ordered from AMRESCO.

Tris-(hydroxym-

ethyl) aminomethane (Tris), Tris-(hydroxyethyl) ethanesufonic acid, ethylenediaminetetraacetic acid (EDTA), nicoti
namide adenine dinucleotide (reduced form, NADH), sodium
dodecyl sulfate (SDS), polyethyleneglycol (PEG), phenylmethylsulfonyl fluoride (PMSF),

fructose 6-phosphate (sodium

salt), fructose 2,6-bisphosphate, adenosine triphosphate
(sodium salt), adenosine monophosphate (sodium salt),
sodium citrate, phosphenolpyruvate, creatine phosphate,
dithiothreitol, 5-bromo-4-cloro-3-indolyl-b-D-galactoside
(X-gal), isopropyl-b-D thiogalactopyranoside (IPTG), ampicillin, kanomycin and chloramphenicol were purchased from
Sigma Chemical Co.

Columns packed with Sephadex G-50 and

G-25 (Select D) were obtained from 5 Prime - 3 Prime, Inc.
(West Chester, PA). Gene clean kit was bought from Bio
101, Inc. (Lo Jolla, CA). Nitrocellulose filters were or
dered from Schleicher and Schuell (Keene, NH). Polyethyleneimine cellulose F plates were purchased from EM Science
(Gibbstown, NJ). Whatman 3MM filter papers were obtained
from Fisher Scientific (Pittsburgh, PA). DEAE cellulose
(DE 52) was bought from Whatman (Hillsboro, OR). Cibacron
blue F3GA-Agarose was ordered from Pierce (Rackford, IL).
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Polaroid film was purchased from Polaroid Co. Filins XAR-5
and XRP-5 was from Eastman Kodak Co.( Rochester, NY).

2.1.3.

Radioactive compounds and oligonucleotides

[a-^PJ-dCTP, [y-32P]-ATP, [a-35S]-dATP and 125I

were

purchased from ICN Biomedicals, Inc. (Irvine, CA) and New
England Nuclear (NEN)/Dupont Co. (Wilmington, DE).
Oligonucleotides were synthesized by solid support
phosphite chemistry (Matteucci and Caruthers, 1981) in an
automated DNA synthesizer (Applied Biosystems Model 380A)
or ordered from American Synthesis Inc. (Pleasanton, CA).

2.1.4.

Vectors, helper phage and bacterial strains

The Lambda ZAP II library containing rabbit muscle
cDNAs, pBluescript KS(+) and KS(-) were purchased from
Stratagene (Lo Jolla, CA). M13mpl6 and ml3mpl9 were or
dered from Boehringer-Mannheim Biochemicals.

The expres

sion vector with the bacteriophage T7 promoter (pET-3c) and
the plasmid carrying the T7 lysozyme gene (Studier et al.,
1990) were gifts from Dr. B. Valdez (Baylor College of
Medicine, Houston, TX). The expression vector with the
lambda PL promoter (pPL2) and the plasmid with a cI857ts
gene (pCI857) (Drahos and Sybalski, 1981) were gifts from
Khorana (MIT, MA). The in vitro mutagenesis vectors
pSELECT-1 and pSELECTE-control were obtained from Promega
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Biotec Corporation.

Helper phage R408 was purchased from

Stratagene and Promega Biotec Corporation.
The bacterial strains used in this work and their
genotypes are listed in Table 2.

E. coli strains HMS174

and BL21(Studier and Moffatt, 1986) were gifts from Dr. B.
Valdez.

E. coli strain DF1020 was kindly provided by Dr.

Barbara Bachmann of the E. coli Genetic Stock Center (Yale
University School of Medicine, New Haven, CT>.

Table 3
Bacterial Strains

E. coll
Strain

Genotype

Reference
or Source
Stratagene
Cat. No.
236211

XLl-Blue

endAl, hsdR17 (rk“,ink ), supE44,
thi-1, lambda”, recA, gyrA96,
relAl, (Iac~*[F', proAB, IacIqZ
M15,TnlO(tetR)].

HMS174

F" recA rK12~mK12+ RifR

Studier
1990

BL21

F~ ompT rB“mB'

Studier
1990

DHSOF1

F', endAl, hsdR17, (rR“,mR ) supE44,
thi-1, recAl, gryA96, relAl,
,
4>80dlacZ _ Ml5 (iacZYAargF) U169

DH5a

F-, endAl, hsdR17 (rK~'mK+*f supE44,
thi-1,recAl, relAl, gyrA96, relAl,
(argF~ laczya)U169, (pSOdlacZ

M15, X

BRL
Cat. No.
8264SA
BRL
Cat. No.
8265SA
Remaut
et al.,
1981

M5219

N+, F' lacZ, trp, SnP~, gall3, chi,
bio, uvrB, (XN7N53cI857H1)

DF1020

pro-82, pfkB201, recA56,
{rha-pfkA)200, endAl, hsdR17,
supE44, thi-1

Kotlarz
et al.,
1982

JM109

endAl, recAl, gyrA96, thi, hsdR17,
{rK”,JrtK_), relAl,supE44, X~,
(lac-proAB),
[F', traD36, proAB, lacIqZ M15]

Promega
cat. No.
Q6210
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Table 3 continued
BMH 71-18
mutS

thi, supE, (Iac“proAB) , [mutS::TnlO] Promega
[F', proA+B+, lacIqZ M15}
Cat. No,
Q6210
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2.2

Methods

2.2.1.
A

Cloning and sequencing of RMPFK cDNAs

lambda ZAP II cDMA library of rabbit muscle was

screened using a partial C-terminal RMPFK cDNA fragment and
a N-terminal RMPFK genomic DNA (exon I) as DNA probes.

The

in vivo excision method was used to excise the pBluescript
phagemid carrying RMPFK cDNA from the lambda vector.

The

RMPFK cDNA inserts were characterized in a plasmid system
by endonuclease mapping and Southern blotting.

Nested

deletion constructs of RMPFK cDNAs were prepared by using
the ExoIII nuclease and Mung Bean nuclease system.

Some

partial RMPFK cDNA fragments were sucloned from pBluescriptRMPFK to M13.

Double stranded and single stranded dideoxy

sequencing methods were used to sequence the deletion
constructs and the partial fragments of RMPFK cDNAs.

2.2.1.1.

Screening of RMPFK cDNAs

A Schematic diagram of the cloning of RMPFK cDNAs
from a lambda ZAPII cDNA library is shown in Figure 7.

The

details of DNA screening and DNA preparation protocols are
described in Appendix VI.

£. coli XLl-Blue cells were

infected with bacteriophage X ZAP and plated on NZY plates.
Approximately 50,000 plaques were plated on a large 150 mm
plate.

Twenty plates were used to screen 1 x 10® plaques.

The plaques were transfered onto nitrocellulose filters in
duplicates.

A

nick translated

DNA

probe corresponding to
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1. Construct cDNA library
2. Isolate positive clone by
screening with nucleic
a d d probe

l i

RMPFK cDNA
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Initiator

Terminator

3. Excise the pBtuescript plasmid
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Amp

RMPFK cONA
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Figure 7 Schematic diagram of isolation of rabbit muscle
PFK CDMA from a XZAFIX cDNA library.
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the 3' end of RMPFK cDNA was used to hybridize the filters
for screening.

Positive plaques, totally 122, were picked

and stored in 1 ml SM with 3 % chloroform at 4°C.

Rapid

phage DNA preparation of these 122 positive plaques were
dotted (approximately 1 jig each) on a nitrocelluose filter.
Dot hybridization was performed by using a ^2p labeled DNA
fragment corresponding to the first exon of RMPFK gene.
Eight positive clones #5, #13, #16, #31, #49, #60, #65 and
#74 were picked up for further characterization.

Approxi

mately 200 plaques of each clone were plated on a small
plate.

The plaques were transfered to nitrocellulose

filters in duplicates.

One filter was hybridized with the

N-terminal DNA fragment of RMPFK gene and the duplicate
filter was hybridized with the C-terminal cDNA of RMPFK to
confirm that the positive clones were full length RMPFK
cDNAs. Three clones #13, #60 and #65 were chosen for the
fourth screening to make sure that they were pure and full
length RMPFK cDNA clones.

A plaque of each clone was

picked and stored in 1 ml SM containing 3 % chloroform at
4°C. The pBluescript phagemid containing the RMPFK cDNA
was excised from the Lambda ZAP II vector by using an in
vivo excision method (Dotto et al., 1984) described in
Appendix VI.

Recombinant phagemid DNA purified by CsCl

centrifugation was used for analysis of

the insert RMPFK

cDNA including mapping of restriction sites and sequencing.
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2.2.1.2.

Endonuclease upping

Restriction enzymes Kpnl, BamHI, EcoRI, Hindlll,
SstI, Smal, PstI were used for restriction mapping of the
cDNA clones.

Digested DNA fragments of each clone were

loaded onto a 0.8 % agarose gel in lx TBE buffer and the
gel was run at 50 volts.

After the completion of gel

electrophoresis, the DNA fragments were transfered to two
nitrocellulose filters by using the Southern hybridization
method (Maniatis et al., 1982) described in Appendix VI.
The nitrocellulose filters were hybridized with both the Nterminal DNA probe and the C-terminal DNA probe described
in section 2.2.1.A.

2.2.1.3.

Heated Deletion, DNA eubcloning end DNA
Sequencing

Clones #13 and #65 were chosen for nested deletion
and DNA sequencing analyses.

A sequencing primer

complementary to the N-terminal 25 bases of RMPFK cDNA and
the Ml3 universal primer were used for sequence analysis of
clones #13 and #65 before performing the nested deletion
reactions. The ExoIII and Mung bean nuclease deletion
system (Stratagene's manual, 1989) was used to produce
unidirectional deletions of predicable sizes of RMPFK cDNA
clones #13 and #65 (details are described in Appendix IX).
Briefly, the double-stranded pBluescript SK(-) phagemid DNA
containing the RMPFK cDNA

was double digested with
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restriction enzymes Kpnl and EcoRV, which are unique sites
in this phagemid DNA.

Deletion reactions were carried out

using ExoIII and Mung bean nuclease.

The deletions were

created in the RMPFK cDNA insert but not in the vector
pBluescript SK(-). The deleted DNA was ligated, trans
formed into XLl-Blue cells, and plated onto LB/ampicillin
plates.

The phagemid DNA of 12 to 24 colonies was isolated

for each deletion construct, digested with Clal or Xbal,
and analyzed by electrophoresis on a 0.6 % agarose gel to
screen the predicted size of the deletion product.

Six

nested deleted constructs of cDNA clone #13 and four delet
ed constructs of clone #65 were analyzed for DNA sequence.
The DNA sequencing reactions were performed by the doublestranded sequencing method (Zhang et al.f 1968) described
in Appendix X.

To complete the sequencing of the full

length RMPFK cDNA, the recombinant phagemids of clones #13
and #65 were digested with several different restriction
enzymes to generate the appropriate RMPFK cDNA fragments.
These partial RMPFK cDNA fragments were then subcloned into
M13 RF as described in Appendix VIII.
sequencing method was used
the full length RMPFK cDNAs.

The single-stranded

to accomplish the sequencing of
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2.2.2.

Kxpr«ssion of RMPFK in X. coli hosts

Several E. coli expression systems were tested for
expression of recombinant RMPFK.

Two of these systems are

presented in this section.

2.2.2.1.

Use of T7 rma polymsrass to direct the

expression of cloned RMPFK
In the T7 RNA polymerase expression system, T7 RNA
polymerase is produced in the cell from the transduced gene
by IPTG induction (Studier et al., 1990).
E. coli BL21(DE3), contain

The host cells,

a lambda derivative bacterioph

age DE3 which carries the l a d gene, the lac UV5 promoter,
the beginning of the lacZ gene, and the gene for T7 RNA
polymerase.

The promoter, lac UV5, controlling transcrip

tion of the T7 RNA polymerase gene is inducible by IPTG.
The pET-3C vector for cloning and expression RMPFK cDNA is
derived from the multi-copy plasmid pBR322.

It carries a

T7 promoter followed by a unique cloning site and a tran
scription terminator,

2.2.2.1.1.

Subcloning

A schematic diagram of subcloning of RMPFK cDNA into
pET-3C is shown in Figure 8.

The expression vector pET-3C

was reconstructed by inserting a Xbal-BamHI linker contain
ing the Shine-Dalgarno sequence and restriction sites Smal
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A m p 1-

E c o R Ii iK p n l

EcoR E

iK pnl

BamH I

Nda I

^ ^B am H I
A 'np'W

RMPFK
Nda I+BamH I

EcoR I

EcoR 2
BamH I
Kpn I
Nda I
Xba I
IJkpn I

Xba I+Kpn I

RMPFKcDNA

TAA

X baI+ K pnI

DNA ligase

DNA ligase

EcoR 2
Kpn 1
♦10^ x b a I

♦ 10 /X b a I
RMPFKcDNA
&
pET-3c/RMPFK

Te NKpnI

rigure 6.
Subcloning of RMPFK cDHA Into pET-3c expression
vector.
The experimental procedure Is described In sec
tion 2.2.2.1.1. The recombinant plasmid was used to
transform Into E, coll BL2KDE3) cells. 010: T7 promoter,
T$: transcription terminator

and Kpnl in the region between the T7<pl0 promoter and the
transcription terminator.

The sequence of the synthetic

linker is shown in Appendix II,

RMPFK cDNA and the

modified pET-3C vector were digested with Xbal and Kpnl.
Fragments of interest were purified by electrophoresis on a
0.8% low melting point agarose gel.

The 3.0 Kb RMPFK cDNA

and the pET-3C bands were cut from the gel and purified
following the procedure described in Appendix VIII.

Liga

tion and transformation reactions were performed as de
scribed in Appendix VIII.

E. coli HMS174 strain was used

as the host for initial cloning and analysis of recombinant
plasmids.

The 5' untranslated region and the first 140

base pairs coding region of RMPFK cDNA were sequenced by
using the double-stranded sequencing method in order to
confirm that RMPFK cDNA was located at the correct position
for expression.

The recombinant plasmid pET-3C/RMPFK was

then transformed into E. coli BL21(DE3) cells for expres
sion.

2.2.2.1.2.

Expression

BL21{DE3) cells carrying the pET-3C/RMPFK plasmid
were grown in M9 medium containing 20 |ig ampicillin/ml,
IPTG was added to the level of
reached an AgQQ of 0.4.
induction.

1 dim when the culture

Cells were harvested 3 hours after

Aliquots of 1 ml of the cell culture was
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collected every hour for analyzing the recombinant protein
by SDS polyacrylamide gel electrophoresis.

2.2.2.1.3.

Analysis of ths raconblnant protaln

Cloned RMPFK was analyzed by gel electrophoresis on
8% gradient acrylamide gels.

A pulse-chase experiment was

also performed to detect the relatively small amount of
cloned RMPFK synthesized in the B.coll cells.

Typically, 1

pCi of 35S methionine was added into 50 Hi of cell culture.
The labeling was allowed to proceed for 3 minutes.

The

cells were collected by centrifugation and resuspended in 1
x sample buffer described in Appendix V,

Total cell con

tents were analyzed by placing 40 jil of the resuspended
cells in the sample buffer, heating 2-3 minutes in a boil
ing water bath, and applying directly to the gel.

The pro

cedure of staining, destaining and transfer was followed as
described in Appendix XII.

Antibody against mammalian PFK

was used for Western blotting.

2.2.2.2.

The expression system driven by heat

shock controlled laaibda pFL2 promoter
(Ramaut, et al., 1981):
The expression vector pPL2 carries a lambda PL
promoter which is under the control of the thermolabile
lambda repressor (lambda cl857 repressor). The host E.
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coli strain, DF1020, is deficient in PFK (Daldal, 1983).
The cl857 plasmid encodes the thermo-sensitive mutant of
lambda cl repressor {Remaut, et al., 1981).

This cl857

plasmid encoding the temperature sensitive mutant of Cl
repressor was cotransformed with the recombinant pPL2 plas
mid into DF1020 cells for expression.
A schematic diagram of subcloning of RMPFK cDNA into
pPL2 is shown in Figure 9.

A synthetic cloning linker was

inserted into the expression vector pPL2 and the cloning
shuttle vector pBluescript KS(+).

This cloning linker

contained the Shine-Dalgarno sequence and the unique clon
ing sites ClaZ, XbaI, EcoRV, Kpnl and Sacl.

The sequences

of the synthetic oligonucleotides are listed in Appendix
II.

The reconstructed pBluescript KS(+) vector and

pBluescript SK(-)/RMPFK were digested with EcoRV and Xbal.
The full length RMPFK cDNA flanked by Xbal and EcoRV sites
was inserted into the reconstructed pBluescript KS<+)
vector. This procedure added a Clal site and the ShingDalgarno sequence at the 5'end and a Kpnl site at the 3'
end of RMPFK cDNA.

The pBluescript KS(+)/RMPFK was trans

formed into DH50CF' cells and plated on agar plates
containing ampicillin.

Plasmid DNA preparations of 12

colonies were digested with SstI which is a unique site in
RMPFK cDNA.

The electrophoretic patterns of digests were

thus used as a selection for pBluescript KS(+)/RMPFK.

The

,Sac I
Transcription Terminator
EcoR I

uescriptKS(

UJ

ClaI
Sac I

Cta I+Sac I
RMPFK cDNA

Cla I
pSluescriptKS(+)yriS^ a j
EcoR
Kpn I
Xba I+EcoR3Z Sac I
DNA ligase

-E coR I

Cla I+Kpn I
pBluescriptKS(+y
RMPFK

Cla I+Kpn

> DNA ligase

RMPFKcDNA

RMPFKcDNA

CI857
pPL2/RMPFK
Ampr

orjX

Term
EcoR I

Figure 9.
Subcloning of RMPFK cDKA into the lambda pPL2
expression vector. The experimental procedure has been
described in section 2.2.2.2. The recombinant plasmid was
used to cotransform with cI857 into E. coli DF1020.

DNA of pBluescript KS (+)/RMPFK was then digested with Clal
and Kpnl.

This full length RMPFK cDNA insert was cloned

into the reconstructed pPL2 which had been digested with
Clal and Kpnl.

pPL2/RMPFK was transformed into E. coll

M5219 strain carrying a defective prophage encoding the
cI857 thermo-sensitive repressor (Remaut, et al., 1981).
Colonies grown on ampicillin plates were screened by direct
double-stranded DNA sequencing of miniprepared plasmid DNA
from 4 colonies.

Postive clones were selected for

preparation of a large quantity of pPL2/RMPFK plasmid.
The DNA of pPL2/RMPFK was cotransformed with cl857
plasmid into E. coll DF1020 and plated onto
containing ampicillin and kanamycin.
incubated at 28°C for 30 hours.

plates

These plates were

Four representative

transformants were streaked on the selective plate (M63
minimal media containing mannitol) and the non-selective
plate (M63 minimal media containing glycerol). Cells con
taining expressed RMPFK grew on the M63/mannitol plate.
Positive colonies were streaked on plates containing ampi
cillin and kanamycin.

A single colony from each plate was

inoculated in 2 ml 2 x YT and grown overnight. Three hun
dred M.1 of overnight cell culture was added into 30 ml 2 x
YT and grown to reach AgQQ « 0.7 at 28°C, heat shocked at
45°C for 30 minutes, and then allowed to grow at 42°C for 3
hours.

Twenty-five ml of cell cultures was harvested and
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sonicated in 1 ml sonication buffer.

RMPFK was detected by

SDS-PAGE and enzyme activity assay as described in Section
2.2.4.

2.2.3.
2.2.3.1.

Purification of recombinant RMPFK
Growing cells and sonication

A single colony of transformed DF1020 was used to
inoculate 2 ml 2 x YT medium containing 200 jig/ml ampicil
lin and 100 }ig/ml kanamycin.

This was grown 24 hours at

28°C in a water bath shaker.

One-half ml of the 24 hour

culture was mixed with 100 ml 2 x YT containing 200 p.g/ml
ampicillin and 100 Jig/ml kanamycin.

After 10 hours of in

cubation at 28°C, a portion of this cell culture (20 ml)
was mixed with 1 liter 2 x YT containing 100 )ig/ml ampicil
lin and 50 ^ig/ml kanamycin.
until AgQQ = 0.95 to 1.0.

This was incubated at 28°C
To bring the liquid to 42°C rap

idly, 500 ml 2 x YT preheated to 70°C was poured into the
cell culture with continuous shaking, and then incubated at
42°C for 3.5 hours.
A total of 4.5 liters of cell culture were pelleted
by centrifugation at 4°C, 6,000 x g for 20 minutes.

The

wet cell pellet was weighed and resuspended at 15% (w/v) in
sonication buffer (Appendix V). Cell suspension was
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transferee! to a 400 ml plastic beaker and sonicated (pulse,
50%, level 6, 50%, horn tip) at 0°C for 2 minutes.

This

was repeated 5 times with 2 minutes cooling intervals.

The

crude cell lysate was spun at 4°C for 1 hour at 12000 x g
for 1 hour.

The supernatant was saved and the cell pellet

was resuspended in 30 ml sonication buffer and sonicated as
described above 3 additional times.

2.2.3.2.

Ammonium sulfate precipitation

Powdered (NH^^SO^ was slowly added into the crude
extract up to 35% saturation.

This was gently stirred in

an ice water bath for 1 hour.

The milky suspension was

centrifuged for 30 minutes at 12,000 x g, 4°C.

Powdered

(NH^^SO^ was slowly added into the clear supernatant to
55% saturation, cooled in an ice water bath for 2 to 4
hours, and centrifuged for 1 hour at 12,000 x g, 4°C.

The

pellet was resuspended in 20 ml of column buffer as
described in Appendix V.

This protein solution was dia-

lyzed against 4 liters of column buffer overnight with 2
changes.

Aliquots were saved for the PFK activity assay,

protein concentration assay and SDS-PAGE analysis.

2.2.3.3.

Cibacron blue F3GA agarose column

Cibacron Blue F3GA Agarose (100 ml) was suspended in
column buffer.

The resin was transferred to a Bio-Rad
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column <30 x 2.5 cm) without trapping air bubbles.

The

resin was equilibrated with column buffer at 4°C, at a flow
rate of 1 ml/min for overnight.

The conductivity of the

equilibrated buffer and the eluate were compared to
determine whether the resin was equilibrated.

The protein

sample was loaded onto the column and washed with column
buffer until the eluate at 280 nm was almost zero.

The

column buffer containing 5 mM Fru 6-P and 5 mM ATP was used
to elute RMPFK.

Three-ml fractions were collected and PFK

activity was determined using the pH 8.0 assay conditions
described below.

The fractions which contained the

majority of PFK activity were combined, dialyzed against 2
liters of column buffer, and concentrated in an Amicon
ultrafiltration cell.
2.2.3.4.

D U E cellulose (DC 52) coluan

DEAE cellulose (DE 52) <5 g) was suspended in 250 ml
of 0.5 N NaOH for 30 minutes, and washed with H20 until the
pH reached about 9.

This was repeated one more time.

The

resin was then washed with 0.5 N HC1 for 30 minutes and
rinsed with H20 until pH * 6.0. Column

buffer <50 mM Tris-

phosphate, 25 mM NaF, 0.1 mM EDTA, 0.1 mM ATP, 10 mM DTT
and 0,1 mM PMSF) was added to the resin and soaked over
night with 3 changes until the pH of the resin reached
8.0.

Then, the resin was packed into a column <10 x 1.5

cm) and equilibrated with 300 ml column

buffer overnight.
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The protein sample was loaded onto the column and washed
with 500 ml column buffer.
elute PFK activity.

A stepwise elution was used to

Column buffer containing 0.2 M Tris-

phosphate eluted the majority of PFK activity.
of 0.8 ml were collected and combined.

Fractions

PFK activity was

determined using the pH 8.0 assay condition described
below.

The fraction containing PFK activity was dialyzed

and concentrated in a Centricon-30 tube.

The purity of the

collected PFK protein was determined using 8% SDS-PAGE.

2.2.4

Assays of PIT activity (To* t Kanp, 1982)

RMPFK was dialyzed against one liter of dialysis
buffer for 24 hours at 4°C.
were used.

RMPFK in

Two types of dialysis buffer

dialysis buffer I (50 mM Tris, 1 mM

DTT, 0.1 mM EDTA, 0.1 mM ATP, pH 8.0) was used for checking
enzyme activity, and RMPFK in dialysis buffer II (50 mM
TES, 1 mM DTT, 0.1 mM EDTA, 0.1 mM ATP, pH 7.0) was used
for allosteric kinetic studies.

The enzyme solution was

diluted with dilution buffer (50 mM TES, 1 mM DTT, 0.1 mM
EDTA, pH 7.0) prior to assay of PFK for determining
allosteric properties.

The actual concentrations of ATP

and AMP were determined spectrometrically at pH 7.0.
Auxiliary enzymes were mixed (4 mg aldolase, 2.4 mg
glycerol 3-phosphate dehydrogenase and 0.2 mg triose
phosphate isomerase) and dialyzed against 1 liter of 50 mM
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Tris-Cl (pH 8.0) or 50 mM TES (pH 7.0) at 4°C for 16 hours
with two changes of buffer.
PFK activity was measured by an assay coupled to NADH
oxidation as described by Foe and Kemp (1982) . For
determination of enzyme activity, PFK was assayed at pH
8.0.

The reaction mixture contained 50 mM Tris-Cl pH 8.0,

5 mM MgCl2, 1 mM EDTA, ImM DTT, 0.2 mM NADH, ImM ATP, ImM
Fru 6-P, and the following quantities of auxiliary
enzymes:aldolase, 40)ig/ml; glycerolphosphate dehydrogenase,
24 jig/ml; triose phosphate isomerase, 2 jig/ml.

For deter

mination of allosteric regulatory properties of PFK, the
enzyme was assayed at pH 7.0.

The reaction mixture con

tained 50 mM sodium/TES pH 7.0, 150 mM KC1, 5 mM MgCl2, 1
mM EDTA, ImM DTT, and 0.2 mM NADH.

The NADH oxidation was

monitored at 340 nm using the Gilford Response II spectro
photometer at 25°C.

One unit of activity was defined as

the amount that catalyzed the conversion of one jimole of
Fru 6-P to Fru 1,6-P2 per minute (Kemp, 1975).
A.

An example of the standard assay condition for

checking the maximum RMPFK activity is shown as follows:
Reaction mixture for 100 assays:
Stock solution
1 M Tris-Cl (pH 8.0)

Volume (ml)
5.0
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1 M MgCl2

0.5

1 M DTT

0.1

0.5 M EDTA

0.2

20 mM NADH

1.0

H20

to 96 ml

This reaction mixture was kept at 25°C during the assay and
a 0.96 ml aliquot was used per assay.
Each assay contained:
Reagent

Volume (ill)

Auxiliaryenzymes

10

0.1 M Fru 6-P

10

0.1 M ATP

10

PFK (diluted)

10

The amount of PFK used was within the linear rate range.
The reaction was initiated by adding Fru 6-P.
B.

An example of the assay condition for checking the

allosteric regulatory properties of RMPFK is shown as
follows:
Reaction mixture for 100 assays:
Stock solution

Volume (ml)

1 M TES(pH 7.0)

5.0

1 M MgCl2

0.5

1 M KC1

15.0

1 M DTT

0.1

0.5 M EDTA

0.2

64

20 mM NADH

1.0

H2O

to 94 ml

On the day of the experiment, a stock solution was made
that contained all the reagents except ATP, PFK, auxiliary
enzymes and Fru 6-P.

These were added to reaction mix

(0.96 ml) in the following order: 1) ATP, 2) PFK, 3)
auxiliary enzymes, 4) Fru-6-P, with a pause of 4 minutes at
25°C prior to the addition of Fru 6-P.

MgCl2 was always

present with 3 mM higher concentration than ATP.

Inhibi

tors citrate, PEP or creatine phosphate were always added
after the addition of ATP.

Rates were determined for 2 to

4 minutes after the addition of Fru 6-P.

2.2.5

Calculation of kinatic results

Nonlinear regression analysis of experimental data
was performed by using the program InPlot™ (Version 4.0,
1992) with an IBM-PC computer; saturation kinetics for
variation of [Fru 6-P] were determined using the equation
for the MWC model, the Hill equation, or the rectangular
hyperbolic equation.

2.2.6

Protein assay

Protein determination was performed by using
Coomassie brilliant blue dye-binding assay solution provid
ed by Bio-Rad.

Bio-Rad protein assay solution was diluted

65

by distilled water in a 1:5 (v/v) ratio.

The assay

standards were made using known concentrations of bovine
serum albumin at 1, 5, 10, 15 and 20 |ig/100 ill.

One hun

dred ill of each standard was added to 5 ml diluted assay
solution.

The absorbance of each standard (1 ml) at 595 nm

was recorded to create a standard curve using the spectro
photometer Gilford Response II.

The unknown protein

concentration was determined by comparing the absorbance of
several dilutions of

the unknown protein to those of the

standard curve.

2.2.7

Site-directed mutagenesis

Four mutations Q200A (Gln-200 to Ala), Q200E (Gln-200
to Glu), Q200N (Gln-200 to Asn), Q200R (Gln-200 to Arg)were
constructed by using the "Altered Sites in vitro
Mutagenesis" kit purchased from Promega Biotec Corp (Madi
son, Wl). A schematic diagram of the "Altered Sites in
vitro Mutagenesis" procedure is shown in Figure 10.

The

details of the procedure is described in Appendix XIII.
Briefly, the system employes a phagemid vector, pSELECT-1,
which contains two genes for antibiotic resistance.

One of

these genes, for tetracycline resistance, is always func
tional.

The other, for ampicillin resistance, has been

inactivated by an amber codon at a PstI site.

A partial

RMPFK cDNA fragment containing the sequence encoding for

mutagenic
oligo

1. Anneal ampictllin repair
oligo and mutagenic oiigo.

pSELBCT-l/mm

Amp*
2. Synthesize mutant strand
with T4 DMA polymerase
and ligate.

pSELECT-1/RMPFK

Transform BMH 71 -18
mut S. Grow in media
ampidlUn.
Prepare mini-prep DNA.
S. Transform JM1Q9. Select
mutants on ampidilin plates.

Amp

BMPA/r

Screen for mutants by
direct sequencing.

Figure 10.
Schematic diagram of the "Altered Sitea la
vitro Mutagenesis*.
The smtagenesis vector pSELECT-1 m s
purchased from Pronega Biotec Corporation (Madison, MI) .
A partial cDNA fragment of RMPFK was subcloned into the
polylinlcer region of pSELECT-1 plasmid. The procedure for
mutagenesis is described in Appendix XIII.

Gln-200 was subcloned into the polylinker region of
pSELECT-1 plasmid between the EcoRI and BamHI sites.

An

oligonucleotide is provided which restores the ampicillin
resistance to the mutant strand during the mutagenesis
reaction.

This oligonucleotide is annealed to the single

stranded DNA template at the same time as the mutagenic
oligonucleotide (containing the sequence for mutation of
Gln-200 of RMPFK). Subsequent synthesis and ligation of
the mutant link the two oligonucleotides.

The DNA is

transformed into a repair minus strain of E. coli (BMH 7118 mut S) and the cells are grown in the presence of
ampicillin, yielding large numbers of colonies.

Plasmid

DNA isolated from each colony is transformed into E. coli
JM109 cells to ensure proper segregation of mutant and wild
type plasmids.
Plasmid DNA was prepared from colonies randomly
picked from the transformation plates and selected for cor
rect mutation by sequencing reaction using a single dideoxynucleotide triphosphate.

The correctly mutagenized RMPFK

cDNA fragment was excised by digestion with XbaX and BamHI.
This fragment was then religated Into the pPL2/RMPFK plas
mid at correct position.

The recombinant plasmid contain

ing the mutagenized RMPFK cDNA was transformed into E. coli
DF1020 cells for expression.

Purification and assay of mu

tagenized RMPFK were performed as those described for wild
type recombinant RMPFK.

CHAPTER THREE
RESULTS

3.1

Purification and Characterisation of ru11-length
RMPFK cDNAs
3.1.1

DNA screening of rabbit nuacle PFK CDNA
library

Lambda ZAPII phage plaques containing rabbit muscle
cDNA inserts were screened for the PFK cDNA using a
nicked-translated DNA fragment containing the 3' region of
RMPFK cDNA as hybridization probe.

Totally 122 plaques

gave the reproducible signals on duplicate filters from
the first screening.

Figure 11 shows the positive signals

on one of the 20 filters and the duplicate.

Rapid phage

DNA extracted from these 122 plaques were further screened
with an end-labeled DNA fragment containing the 5' region
of RMPFK gene (corresponding to exon I of the gene) by dot
blot hybridization (Figure 12).
ther purified by replating twice.
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Eight plaques were fur
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%

figure 11.
Purification of rabbit muscla PFK cDNA cloned
in lambda ZAPII phage DMA.
XLl-Blue cells CIO®) were In£
fected with the phage particles (10w) and plated onto 20
NZY agarose plates (150 mm).
Nitrocellulose filters (132
mm diameter BA85, Schleicher 6 Schuell) in duplicate were
lifted from each plate and hybridized with nick-translated
3' fragment of RMPFK cDNA. Positive plaques that were
shorn to be present duplicate filters were further screened
by dot hybridization.
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i

Figuzt 12.
Nitrocellulose dot blot hybridisation of full
length RMPFK cDNAs. Lambda ZAPII phage DNA that was
purified from every positive plaque (Figure 11) was dotted
onto a nitrocellulose filter and hybridized with an end la
beled DNA fragment corresponding to exon I of RMPFK gene.
The big spot on the top of this figure is the positive
control (containing probe DNA).
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3.1.2.

Endonuclease upping of RMPFK CDNA clones

Phagemid DNA excised from three purified phage
clones #13, #60 and #65 was characterized by digesting
with several restriction enzymes followed by Southern blot
hybridization using an end-labeled DNA fragment corre
sponding to the first exon of RMPFK gene (Figure 13B, 14B
and 15B) or a nick-translated DNA fragment containing the
3' region of RMPFK cDNA mentioned above (Figure 13C, 14C
and 15C) as probes.

The restriction maps are shown in

Figure 16A, 16B and 16C.
cal restriction maps.

Clones #60 and #65 have identi

However, the restriction map of #13

is different from that of #60 and #65 in the 5' region.

A

sequencing primer complementary to a portion of the first
exon of RMPFK gene was used to sequence clones #13, #60
and #65.

Results of DNA sequence analysis showed that

clones #60 and #65 have a identical sequence in the 5'-un
translated region, but clone #13 has a different sequence
from that of clone #60 and #65 in this region.

Therefore,

clones #13 and #65 were chosen for further characteriza
tion.
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Figure 13.
Nitrocellulose blot hybridization of RMPFK
cDNA fragment* from clona #13.
Purified pBluescriptSK (-)
phagemid DNA containing RMPFK cDNA insert was digested
with BamHI (B), Hindlll (H), EcoRI (E), Kpnl (K), Smal
(Sm), SstI (St) and PstI (P) singly or in combination.
Fragments produced were separated by electrophoresis on an
0.8% agarose gel (A), blotted onto nitrocellulose filters
and hybridized with an end-labeled DNA fragment corre
sponding to exon I of RMPFK gene (B) or blotted with a
nick-translated DNA fragment containing the 3' region of
RMPFK cDNA (C). The size marker (M) was Hindi11-digested
lambda phage DNA. S: Intact pBluescriptSK(-)/RMPFK
plasmid DNA.
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Figure 14.
Nitrocellulose blot hybrid! zmtion of RMPFK
cDNA fragments from cion* #60.
For an explanation of the
method used see Figure 13.
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Nitrocellulose blot hybridization of RMPFK
cDMA fragments from clone #65.
For an explanation of the
method used see Figure 13.
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Raatriction naps of tha full-langth RMPFK cDNA
#13 (A), #60 (B) and #65 (C). Xbal (X), BamHI (B),
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3 .1 .3

Characterisation of full length RMFnt cDNAs

Phagemid DNA containing the full length RMPFK cDNA
of clones #13 and #65 was serially deleted using the
ExolII/Mung bean nuclease deletion method.

Double-strand

ed or single-stranded DNA from six deletion constructs of
clone #13 (Figure 17A) and four deletion constructs of
clone #65 (Figure 17B) were purified and used as templates
for DNA sequence analysis.

The primers used in these

analyses were universal primer and synthetic oligonucle
otides corresponding to or complementary to some codons of
RMPFK.

The sequence analyses were accomplished by sub

cloning several partial cDNA fragments of both clones into
M13 for single-stranded sequencing.

A schematic diagram

of the sequence analyses is shown in Figure 18.

Total se

quence of approximately 3000 bp in the coding region, 5'
untranslated region and 3' untranslated region of both
RMPFK cDNAs have been determined.

The sequence alignment

of these two cDNAs in the coding region and the 3' un
translated region is shown in Appendix I.

The result

shows that the entire coding sequence including 11 bp up
stream of ATG codon and the 3' untranslated region of
these two cDNAs are identical.

The sequence alignment of

the 5' untranslated regions of these two cDNAs shows the
sequence diversity in this region (Figure 19).

A surpris

ing feature in cDNA-A (#65) is the existence of a TATAAAA
sequence in the transcript of the RMPFK gene.
ture will be discussed in Section 4.1.

This fea
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Figure 17.
Nested deletions of full-length FMFFK cDNAs
Purified pBluescript SK(-) phagemid DNA containing deleted
RMPFK cDNA insert was analyzed by electrophoresis on an 0.8
% agarose gel. Six nested deletion products of cDNA 113
are shown in (A) and four nested deletion products of cDNA
#65 are shown in (B). The size marker was Hindlll-digested
lambda phage DNA or 1 Kb DNA ladder. Purified pBluescript
SK(-) phagemid DNA containing full-length RMPFK cDNA is
shown in lane 1 of both (A) and (B).
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Kb L

rigura 18.
Saquancing stratagias used to saquanca fulllangth RHPFK CDNA 13 (A) and cDMA 65 <B). Top line, scale
In Kb; arrows, fragments subcloned in M13mpl8 or mpl9 phage
vectors, or deletion constructs (described in Figure 17}.
The directions of sequencing are indicated by arrow heads.

cDNA-A

CTCTCCGGAG GTATAAAACG TGAGAGGGGC AGGCTGCTGA CCCCCAATCT

cDNA-A
cDNA-B

AGTCCAAACC CTTCTTAGTG CATAAGAAGC TGTTCAAGTC CCACACAAGG
TGTCC TAACTGACCA TCGTCTTGCC

cDNA-A
cDNA-B

TATTAGAGTG GATC ATG ACC CAT GAA___
TTCTAGAGTG GATC ATG ACC CAT GAA___
M
T
a
c ___

Figure 19.
Sequence diversity in ths 5'-untranslated re
gion of rabbit aiuscle PIT cDNA.
Bold prints indicate
identical sequences. Plain prints are diverse sequence.
"TATA" box is underlined. Coding sequences downstream of
ATG codon are identical in cDNA-A (corresponding to cDNA
65) and cDNA-B (corresponding to cDNA 13) (for sequence
comparison of the coding region and the 3' untranslated re
gion of both cDNAs see Appendix I).
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3.2.

Expression of Rabbit Muscle PrK in t. coli

3.2.1.

Expression of RMPFK

Two types of expression systems have been used in
this study.

The first system is under the control of T7

promoter, whereas the second one is driven by the lambda
pPL2 promoter.

SDS-PAGE and Western blot analysis show

that the transformation of E. coli BL21(DE3) with pET3c/RMPFK expresses RMPFK after IPTG induction ^(Figure 20).
RMPFK produced in E. coli BL21(DE3) is the same size as
the authentic protein which is 85 KDa.
The transformation of E, coli DF1020 with pPL2/RMPFK
and pCI857 and subsequent plating on selective plate
M63/mannitol shows that cloned RMPFK has been expressed in
E. coli DF1020 (region II, IV, V in plate A) (Figure 21).
SDA-PAGE shows a significant level of RMPFK expression
(Figure 22).

In addition, the pFL2/DF1020 expression has

an advantage of providing a visible selection for clones
which express RMPFK.

This system has been used throughout

this work for the expression of wild type and mutant
RMPFK.
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rigure 20.
itastern blot of recombinant RMPFK protein.
Lane 1: pure RMPFK from Sigma; lane 2: E. coli
BL21(DE3), not transformed; lane 3: E. coli BL21(DE3),
transformed with pET-3c vector; lane 4: E. coli BL21(DE3),
transformed with pET-3c/RMPFK, uninduced; lane 5-7: E. coli
BL21(DE3), transformed with pET-3c/RMPFK, IPTG induced, and
further grown for lhr (5), 2 hrs (6), and 3 hrs (7). Posi
tion of recombinant RMPFK is indicated by an arrow. The
other bands are E . coli proteins that cross-link with rat
anti-PFK antibody.
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Figure 21.
Selective plat* demonstrating tha expression
of elonad RMPFK in E. coli DF1020. Plate (A): M63 minimal
media containing mannitol, Plate (B) : M63 minimal media
containing glycerol;
I: E, co2i DF1020, not transformed;
II, III, IV, V: pPL2/RMPFK and pCI857 cotransformed into
DF1020; VI: pPL2 and pCl857 cotransformed into DF1020.
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Figure 22.
SDS-PAGE analysis on tba axprasslon of
racoeibinant RMPFK in X. coil DF1020. The samples are pre
pared directly from crude extracts of E. coll cells. Lane
1: E. coll DF1020, transformed with pPL2/RMPFK, uninduced;
lane 2-5; E, coll DF1020, transformed with pPL2/RMPFK,
induced by heat shock, and further grown for lhr (2), 2 hrs
(3), 3 hrs (4), 4 hrs (5), and ; lane 6: RMPFK from Sigma;
lane 7: E. coll DF1020, transformed with pPL2 vector; Lane
8: E. coll DF1020 not transformed; M * Size Markers (BioRad) . All transformations were carried out by co-transfor
mation with pCX857. Position of recombinant RMPFK is indi
cated by an arrow. The density of some other protein bands
also increased during induction. These proteins may be E.
coll heat shock proteins.

86

3.2.2.

Purification of RMPFK from X. aoll DF1020

The purification procedure has been described in
Section 2.2.3.

It includes ammonium sulfate

precipitation, and chromatography using an affinity column
(Cibacron Blue F3GA-agarose) and an ion exchange column
(DEAE cellulose). The results of wild-type RMPFK purifi
cation are shown in Figure 23 and Table 4.
The result of SDS-PAGE shows that wild-type RMPFK
has been purified.

Approximately 1000-fold purification

is achieved during the purification of RMPFK from B. coll
DF1020 (Table 4).

The recovery is 710 ng of purified

RMPFK from 4.5 liters of E. coli culture.

This scale is

suitable for the enzymological studies reported here.

3.2.3.

Comparison of the cloned and the authentic
RMPFK

SDS-PAGE shows that the cloned RMPFK has the same
molecular weight as that of authentic RMPFK (Figure 22 and
23).

Enzyme kinetic studies prove that they have the same

kinetic values with respect to Fru 6-P and ATP
concentration (Table 5) at pH 7.0 and pH 8.0.

The specif

ic activity of the recombinant RMPFK is slightly lower
than the reported value.

Although the DEAE cellulose pu

rified enzyme showed to be a single band on SDS-PAGE, the
preparation may contain some inactive PFK protein.

The

inactive PFK protein has the same chromatographic and
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M

1
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3

97.400

66,200

31,000
31,300
14.400

Tigura 23.
SDS-PAOE analysis of the purification of
raconbinant BMPFK.
Lane 1: RMPFK from Sigma Chemical Co.
lane 2 : crude extract
lane 3: ammonium sulfate fraction (35 % to 55 % sat'n)
lane 4: after Cibacron blue F3GA column
lane 5: after DEAE cellulose column
M: size markers

Table 4.
Purification of racoobinant RMFTK from X. coll DP1020

Step

Total
volume
ml

Total
Protein
mg

Total
Activity
U

Specific
Activity
U/mg

Recovery
%

Crude
extract

135

2200

283

0.13

100

Ammonium
sulfate

26

450

241

0.52

89

Cibacron
F3GA

12

6.6

173

26

61

0.71

126

180

49

DEAE

0.94

* One unit of activity is defined as a change in absor
bance at 340 nm of 12.4 per min (Kemp, 1982). Protein
concentrations were determined as described in Section
2 .2 .6 .
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Table 5.
(A)
Comparison of the kinetic parameters between
commercial RMPFK and recombinant RMPFK at pH 8.0.
Enzyme Form
RMPFK
(from Sigma)
RMPFK
(cloned)

Specific Activity
(units/mg)

Km (app)
Km (app)
Fru 6-P (mM) ATP (mM)

220*

0.21 ± 0.041

0.09 ± 0.013

180

0.18 ± 0.043

0.10 ± 0.021

Enzymes were assayed as described in Section 2.2.2.4.
The Km (app) was determined by using the Rectangular
hyperbolic equation (Y * A*X/B+X; A=Vmax, B*Km). The Km
(app) for Fru 6-P was determined by measuring enzyme ac
tivity while varying Fru-6-P concentration from 0.05 mM to
2 mM with a constant ATP concentration of 1 mM. The Km
(app) for ATP was determined by measuring enzyme activity
while varying ATP concentration from 0.1 mM to 2 mM with a
saturating Fru 6-P concentration of 1 mM. The value of
the Km is presented with a standard error value.
♦Data from product profile of RMPFK purchased from Sigma.

(B)
Comparison of the kinetic parameters between
commercial RMPFK and recombinant RMPFK at pH 7.0.
Enzyme Form
RMPFK
(from Sigma)
RMPFK
(cloned)

Specific Activity
(units/mg)

Km (app)
Fru 6-P (mM)

170

0.40 ± 0.042

140

0.46 +. 0.073

The Km (app) was determined from the Hill plot ( a
double logarithmic plot of log(v/l-v) vs. log[SJ) using
the program Inplot™ on an IBM PC. The Km (app) for Fru6-P was determined by measuring enzyme activity while
varying Fru-6-P concentration from 0.05 mM to 2 mM with a
constant ATP concentration of 1 mM. The value of the Km
is presented with a standard error value.
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electrophoretic mobility as the active protein.

The wash

ing buffer containing NAD and ADP may remove the inactive
PFK protein during chromatography of the enzyme using Ci
bacron F3GA agarose (Dunaway, personal communication),
The elution buffer containing Fru 6-P, ATP and EDTA would
recover PFK with high specific activity.

3.3.

Mutation of Gln-200 to Alanine, to Arginine, to
Asparagine and to Glutamate

3.3.1.

Mutation and the expression of mutants

Site-specific mutants of cloned RMPFK are
constructed for the purpose of investigating the allosteric properties of this enzyme.

The following point muta

tions are introduced by using the Promega in vitro mu
tagenesis kit (Figure 10): Gln-200 (CAG) to Ala (GCG)
(Q200A), Arg (CGG) (Q200R), Asn (AAT) (Q200N) and Glu
(GAG) (Q200E). The mutants are identified by sequencing
randomly selected colonies after the mutagenesis reactions
(Figure 24).

The nucleotide sequences of these mutant

codons are shown in Figure 25.
The results of selective plating on M63/mannitol
show that mutants Q200A, Q200R and Q200E are expressed in
£. coli DF1020.

However, expression of Q200N is not de

tected on the selective plate (Figure 26).
this failure in not clear.

The reason for

Three mutants Q200A, Q200R and

Q200E have been purified (Figure 27).
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Figure 24.
Method of screening for mutants.
Track sequencing was used to identify mutants. Sequenc
ing primer PFK 3 (Appendix 1) was used as a primer to
perform a ddA or a ddC sequencing reaction on wild-type
(lane 1, A 4 B), and mutants (lane 2-6, A) (lane 2-5, B)
and these were loaded on a 6% sequencing gel. The arrow
shows the mutants identified.
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Q300A

Q200R

A G C T

A 0 C T

T'
A
A ■

Q200N

Q200K

Figure 25.
ONA sequence showing ths nutations of Gln-200.
In vitro mutation was carried out using a Promega
"Altered Sites in vitro mutagenesis" kit. The method is
described in Appendix XIII. Sequencing was performed by
the dideoxy chain termination method using a "Sequenase"
(USB) kit as described in Appendix IX. WT, wild type.
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Figure 26. Salactiva plat* damonstrating th* expression
of mutants of RMPFK in E.coli DF1020. Plate (A) : M63
minimal media containing mannitol; Plate (B): M63 minimal
media containing glycerol; I. E. coli DF1020; II. E. coli
DF1020, transformed with pPL2 vector and pCI857 plasmid;
III. E. coli DF1020, transformed with wild type
pPL2/RMPFK; IV, V, VI, VII: E. coli DF1020, transformed
with mutated pPL2/RMPFK and pCl857, Q200A (IV), Q200R (V),
Q200N (VI), and Q200E (VII).

97,400

m
66,200

3 1 ,0 0 0
2 1 ,5 0 0
1 4 ,4 0 0

• *

Figure 27.
SD8 -FAGE showing ths purification of mutants
O f RMPFK.
Lane X: RMPFK from SigmaChemical Co.
Lane 2: crude extract ofwild type RMPFK
Lane 3: ammonium sulfate fraction (35% to 55%) of wild type
RMPFK
Lane 4: wild type RMPFK, after Cibacron blue F3GA column
Lane 5: wild type RMPFK, after DEAE
cellulose column
Lane 6: pure Q200A RMPFK
Lane 7: pure Q200R RMPFK
Lane 8: pure Q200E RMPFK
M : size markers

3.3.2.

Comparison of the kinetics of wild typa
FMPTX and the thraa mutants

The recombinant RMPFK and its three mutants, Q200A,
Q200R and Q200E, have different kinetic parameters with
respect to both substrates at pH 7.0 as well as at pH 8.0
(Table 6).

At pH 8.0, the

mutant Q200E is

about 14-fold higher than that of wild type.

Under these

conditions, the mutant Q200A has a 15-fold higher Km^TP)
than wild type (Table 6A). These results indicate that
different mutations at position 200 affect the affinities
of RMPFK for each of the two substrates to different
extents at pH 8.0.

At this pH, inhibition by ATP and co-

operativity of Fru-6-P binding are not present.
At pH 7.0, the effects caused by these mutations are
dramatic.

First of all, the wild type RMPFK and the three

mutants, uninhibited by ATP at pH 8.0, are now subject to
ATP inhibition.

When activity is measured against ATP

concentration, the activity of the wild type enzyme
increase rapidly, then starts to drop at 0.6 mM ATP.

On

the other hand, the activity of the Q200R mutant keeps in
creasing up to 7 mM ATP.

The effect of ATP concentration

on the Q200E mutant can only be observed at 50 mM Fru 6-P
(Figure 28), and the activity of the Q200A mutant is too
low at pH 7.0 for proper analysis.

The conditions neces

sary for investigating the cooperative binding of Fru 6-P
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Table 6.
(A)
Effect of Gln-200 mutation on the kinetic parameters
of RMPFK at pH 8.0.
Enzyme Form
wild Type
(cloned)
Q200R

Specific Activity Km (app)
(units/mg)
Fru 6 - P (mM)

Km (app)
A TP (mM)

180

0.18 ± 0.042

0.10 ± 0.025

110

0.22 ± 0.021

0.47 ± 0.030

Q200E

44

2.5 ± 0.53

0.49 ± 0.061

Q200A

140

0.42 ± 0.038

1.3 ± 0.17

The Km (app) was determined as described in Table 5A.
The Km (app) for Fru 6-P was determined by measuring en
zyme activity while varying Fru 6-P concentration with a
optimal ATP concentration (1 mM for wild type, 4 mM for
Q200A and Q200R, and 2 mM for Q200E). The Km (app) for
ATP was determined by measuring enzyme activity while
varying ATP concentration with a saturating Fru 6-P
concentration (2 mM for wild type, Q200R and Q200A; 10 mM
for Q200E). The value of the Km is presented with stan
dard error.
<B)
Effect of Gln-200 mutation on the kinetic parameters
of RMPFK at pH 7.0.
Enzyme Form
Wild Type
(cloned)
Q200R

Specific Activity Km (app)
(units/mg)
Fru 6-P (mM)

Hill #
n

150

2.00 ± 0.061

2.4 ± 0.43

85

0.51 ± 0.025

1.9 ± 0.22

Q200E

16

28 ± 1.7

1.0 ± 0.40

Q200A

N.D.

N.D.

N.D.

The Km (app) for Fru-6-P and the Hill coefficient n
were determined from a Hill plot as described in Table 5B.
The Km (app) for Fru 6-P was determined by measuring en
zyme activity while varying Fru 6-P with a constant ATP
concentration of 7 mM. The units of wild type, Q200A,
Q200R and Q200E were adjusted to the same level at pH 8.0
as described by Foe and Kemp (1982). The determinations
were made at optimal concentrations of Fru-6-P and ATP for
all PFKs at pH 8.0. Activity of each enzyme at pH 7.0 was
also measured as described by Foe and Kemp (1982).
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Figure 28.
Effecta of ATP concentrations on the activity
of the wild type RMPFK and its mutants. wild type ( •),
Q200R (a), Q200E (□) Q200A (A)/ Relative activity is
based on the maximum activity of the enzyme in the pres
ence of saturating concentrations of Fru-6-P and ATP at pH
8.0 as listed in Table 6A. The effect of ATP concentra
tion on the enzyme was determined with a constant Fru 6-P
concentration of ImM (for wild type and Q200R mutant), or
50 mM (for Q200B and Q200A mutants) at pH 7.0.
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,ie., pH 7.0 and 7 mM ATP, were chosen based on these
results.

Because an ATP concentration of 7 mM is required

for maximum activity of the Q200R mutant, all studies for
which Km (app) and the Hill coefficient for the wild type
enzyme and the three mutants are compared use an ATP con
centration of 7 mM.

Under these conditions (Table 6B,

Figures 29 A, B), RMPFK is initially in the T conforma
tion; thus it binds Fru-6-P cooperatively and responds to
the concentrations of the effectors (Fru 2,6-P2 or
citrate)

(Figures 30, 31, 32, 33).

The data in Table 6B summarizes the behavior of the
wild type enzyme and the three mutants.

The data have

been obtained from the sigmoidal saturation curve (rela
tive activity vs. Fru 6-P concentration) of each enzyme.
The half saturation concentration, Km (app), and the Hill
coefficients were both ultimately derived from the sigmoi
dal saturation curves.

Both the Km (app)(Fru 6-P) and the

Hill coefficient were determined directly from the Hill
plot.

The Km (app) for Fru 6-P of the Q200R mutant is 4-

fold lower than that of the wild type enzyme, while the Km
(app) for Fru 6-P of Q200E mutant is 14-fold higher than
that of the wild type enzyme.

The activity of the Q200A

mutant is too low at pH 7.0 to allow accurate analysis of
the effect of Fru-6-P concentration.

The value of the

Hill coefficients for the enzymes vary from n - 2.4 i 0.43
(for wild type enzyme) to n * 1.9 +. 0.22 (for Q200R
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mutant) and n - 1.0 +. 0.40 (for Q200E mutant)

(Table 6B) .

A Hill coefficient of 2.8 ±. 0.32 has been determined for
the wild type enzyme at pH 7.0 in the presence of 1 mM
ATP.

This value is comparable to the value of 3.0 ob

tained by Valaitis et al. (1987) for RMPFK Isolated from
rabbit skeletal muscle.

Recall that an ATP concentration

of 7 mM was necessary for the above comparison because of
the nature of the ATP saturation of Q200R.

Q200A mutant

is essentially inactive under the same conditions.

This

mutant cannot achieve half-saturation, even with a concen
tration of Fru-6-P over 200 mM, in the absence of Fru-2,6P2-

The Fru-6-P saturation curves of the wild type enzyme

and the three mutants are shown in Figure 29.
The effects of the activator and inhibitor on the
wild type enzyme and the three mutants are demonstrated
from the results of the Fru 6-P saturation curves (Figure
30, 31, 32 and 33).

After activation by Fru 2,6-P2, the

kinetic data of each enzyme fits to the rectangular
hyperbolic equation much better than before such activa
tion (Table 7).

The justification of the curve-fitting to

the kinetic data will be discussed in Section 3.3.3.
The value found for the Hill coefficient decreases (n 1.4 ± 0.85 for WT; 1.1 + 0.17 for Q200R; 1.2 ± 0.27 for
Q200E, and 1.1 ±. 0.42 for Q200A) upon Fru 2,6-P2
tion even in the presence of 7 mM ATP.

activa

Therefore, ATP

Figure 29.
Comparison of the offset of [Fru 6 -P] on the
activity of the wild typa RMPFK and its mutants; Q200R,
Q200A and Q200E.
(A) wild type (•), Q200R (&), Q200E
( □) Q20QA (A >; The conditions of these experiments are
described in Section 2.2.4 (Foe and Kemp 1982). The a s says were performed at pH 7.0 in the presence of 7 mM ATP.
Relative activity is based on the maximum activity of the
enzyme in the presence of saturating concentrations of
Fru-6-P and ATP at pH 8.0 as listed in Table 6A. (B) Ten
fold higher concentration of Fru-6-P than that in (A).
Q200E (□ ) Q200A (A ) .
The equation for the MWC model (equation I, for de
scribing the cooperative saturating curves) that was used
by Inplot™ is (Y « C* [(X/A) * (1+ (X/A) )3]/ [(1+ (X/A) )4+B], A
* KR, B - L, equilibrium constant for the T * R
interconversion, C - Vmax) The rectangular hyperbolic
equation (equation II) that was used by Inplot™ is (Y *
A*X/(B+X); A ■ Vmax, B - Km). These equations were used
for curve fitting to the kinetic data of each enzyme. The
evaluation of goodness-of-fit of these two equations
fitted to the same data is presented by comparing the sumof-squares value calculated.
The sum-of-squares values of these two types of
curve fitting (I/II) are shown as follows:
wild type (0.0019/0.11), Q200R (0.040/0.17), Q200E
(0.0044/0.0091). The curves were drawn using the equation
based on the MWC model. Since the Q200A mutant is
essentially inactive, the linear regression program was
used to draw the line.
The values of the parameters used in both equations
are listed in Table 7.
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Figure 30.
Effects of Fru-2,6-^2 ■“<* citrate on recombi
nant RMFnc (wild type). Initial velocities were measured
in the absence of effectors(• ) or in the presence of 1 JiM
Fru-2,6-P2 (O) or 75 |1M citrate (#). The assay condi
tions were the same as described in Section 2.2.4., Table
6B and Figure 29. The equation for the MWC model (equa
tion I) and the rectangular hyperbolic equation (equation
II) were used to fit to the kinetic data.
The sum-of-squares values of these two types of
curve fitting <I/II) are shown as follows: enzyme in the
absence of effector (0.0019/0.11), enzvme In the presence
of F-2.6-P^ (0.011/0.038), enzvme In the presence of
citrate (0.000 95/0.0045). The curves were drawn using the
equation based on the MWC model.
The values of the parameters for both equations (I
and II) are listed in Table 7.
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Figure 31.
Effects of Fru-2,6-P2 end citrate on recombi
nant RMPFK (Q200R). Initial velocities were measured in
the absence of effectors(A ) or in the presence of 1 HM
Fru-2,6-P2 (O) or 125 jam citrate (♦). The assay
conditions were the same as described in Section 2.2.4.,
Table 6B and Figure 29. The equation for the MWC model
(equation I) (for describing the sigmoidal saturating
curves) and the rectangular hyperbolic equation (equation
II) were used to fit to the kinetic data.
The sum-of-squares values of these two types of
curve fitting (I/II) are shown as the follows: enzvme in
the absence of effector (0.040/0.17), enzvme in the pres
ence of F-2.6-F^ (0.035/0.0043), enzvme in the presence
of citrate (0.00013/0.00099). The curves for the
reactions in the absence of effector and in the presence
of citrate were drawn using the equation based on the MWC
model. The curve for the reactions in the presence of Fru
2,6-P2 was drawn using the rectangular hyperbolic equa
tion.
The values of the parameters for both equations are
listed in Table 7.
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Figure 32.
X£ftcfca of Fru-2,6-F2 end citrate on recoobi
nant RMPFK (Q200E). Initial velocities were measured in
the absence of effectors(O) or in the presence of 10 nM
Fru-2, 6-p2 (O) or 25
citrate (♦). The assay condi
tions were the same as described in Section 2.2.4, Table
6B and Figure 29. The equation for the MWC model (equa
tion I) and the rectangular hyperbolic equation (equation
II) were used to fit to the kinetic data.
The sum-of-squares values of these two types of
curve fitting (I/II) are shown as the follows: enzyme In
the presence of F-2.6-P^ (0.008/0.022), enzvme in the ab
s e n c e Qff .fifff id L Q C or enzvme in the presence of citrate
could not be determined in this range. The curves were
drawn using the equation based on the MWC model or using
the linear regression program.
The values of the parameters used in both equations
are listed in Table 7.
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Figure 33.
Effects of Fru-2,6-?2 end citrate on recombi
nant RMPFK (Q200A) . Initial velocities were measured in
the absence of effectors(A) or in the presence of 10 JIM
Fru-2,6-P2 (O) or 25
citrate (♦). The assay condi
tions were the same as described in Section 2.2.4., Table
6B and Figure 29. The equation for the MWC model (equa
tion I) and the rectangular hyperbolic equation (II) were
used to fit to the kinetic data.
The sum-of-squares values of these two types of
curve fitting (I/II) are shown as follows: enzyme in the
presence flf F-2.6-P^ (0.OlO/O.039), enzvme in the absence
Of effector or enzvme in the presence of citrate could not
be determined in this range. The curves were drawn using
the equation based on the MWC model or using the linear
regression program.
The values of the parameters used in both equations
are listed in Table 7.

Table 7
P>r—

tirt for curve-fitting to the data of the wild typo RMPFK and tho throe octants

MSC

Enzyaa E ffector
*R

L

Vaax

sue-of

Vnax

Kb

aun-of
squares

■quarts

NT

non*

0.90 ± 0-019 2900 X 3200 0.90 ± 0.02

0.0019
0.011

wr

Fru 2,«-P2

0.S7 ± 0.14

11 X 0.3

1.1 ± 0.03

WT

C itra te

4.5 ± 2.3

1 8 ± 20

0.76 ± 0.17

020(0

non*

0.079 X 0.034

Q200R Fru 2.0 -P2 0.057 X 0.0090
Q200R

C itra te

5.8 ± 0.84

Q200E

non*

24 X 0-0

Q200E Fru 2,6 -P2 0.34 X 0.042

1.6 ± 0.46

1.4 ± 0.85

0.58 ± 0.16

0.17

1.9 ± 0.22

0.99 ± 0.011 0.035

1.0 ± 0.03

0.12 ± 0.024

0.043

1.1 ± 0.17

1.3 ± 0.21

15 ± 3.5

0.00099

0.72 ± 0.12

63 ± 20

0.0091

1.0 ± 0.40

0.54 ± 0.07S

0.022

1.2 ± 0.27

54 X 32

1.7 X 0.60 0.84 X 0.051 0.00013
S .6 ± 5.3

0.52 ± 0.0S2 0.0044

7.2 ± 3.4

0.96 ± 0.17

0.008

1.0 ± 0.04

N.D.

N.D.

N.D.

N.D.

0200ft

nans

N.D.

N.D.

N.D.

N.D.

N.D.

13 A 9.6

1.0 ± 0.34

N.D.

N.D.

N.D.

2.4 ± 0.43

1.0 ± 0.08

N.D.

C itra te

0.11

1800 ± 1900 0.91 ± 0.021 0.040

C itn t*

0200ft

6.5 ± 0.37

1.2 ± 0.25
0.038
1.2 ± 0.06
6
7
5
6
0.00095 1.6x10 ± 1.8x10 3.5x10 ± 4.1x10 0.045

Q200E

0200ft Fru 2,6 -P2 0.62 X 0.15

H ill
co efficien t

0.01
N.D.

1.1 ± 0.71
N.D.

N.D.

N.D.

1.5 ± 0.30
N.D.

N.D.

N.D.

0.039
N.D.

N.D.

1.1 ± 0.42
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inhibition of the wild type and of all the mutants is
reversed by Fru-2,6-P2. This suggests that mutations at
position 200 have no effect on the binding site of the ef
fector Fru 2,6-P2 .

3.3.3.

Justification of curve-fitting to kinetic
data

The cooperativity of the binding of a substrate mol
ecule to an allosteric enzyme is represented by a sigmoi
dal saturation curve when enzyme activity is plotted vers
es substrate concentration.

The greater the cooperativi

ty, the greater the sigmoidicity. Two equations were
tested for curve-fitting to the saturation data: either
the equation for the MWC model of allosteric behavior
(equation Is Y - C* [<X/KR)* (1+ <X/KR)>3]/ [(1+ (X/KR))4+L])
or the equation for Michaelis-Menten rectangular hyperbol
ic kinetics (equation II: Y * Vmax*X/Km+X) was used
(Figures 29-33).

The computer software package InPlot™

(Version 4.0) from Graph Pad (San Diego, CA) was used for
curve-fitting and calculation of parameters based on these
two equations. Each fit was evaluated by calculating a
"goodness-of-fit" value, which is the sum-of-squares of
the distances of the data points from the curve.

Further

more, each parameter for the equation used for curve-fit
ting was assigned a standard error value.

The magnitude
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of the standard error value relative to the value of the
parameter itself indicates the confidence one can have
that a given parameter is meaningful.

In order to

confidently analyze the cooperativity of the binding of
the Fru 6-P molecule to the wild type enzyme and the three
mutants, therefore, one must examine the validity of
curve-fitting via goodness-of-fit values, the values for
parameters themselves, and the standard error values as
signed to the parameters.

Table 7 shows 1) the goodness-

of-fit (sum-of-squares) values, 2) the values for the
parameters <KR and L, or Vmax and Km) generated by
Inplot

TM

and used in the equations, and 3) the values of

the Hill coefficients for the wild type enzyme and the
three mutants.

In the absence of Fru 2,6-p2» a comparison

of the goodness-of-fit to the cooperative curve based on
the MWC model vs. the rectangular hyperbolic curve reveals
a better fit to the cooperative curve (Figure 29).

This

is true not only for the wild type enzyme but also for the
two mutants Q200R and Q200E.

A comparison of the KR val

ues and the Hill coefficients of the wild type enzyme and
the Q200R mutant indicates that the cooperative curve fits
to the wild type enzyme data better than it does to the
Q200R mutant data.

Because the standard errors for the L-

value of the wild type enzyme and the Q200R mutant are
large, the parameters may not be suitable for predicting
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the origin of the enzyme's cooperative behavior.

The co

operative curve is not a good fit to the data for the
Q200E mutant probably because saturation of this mutant by
Fru 6-P is not achieved.

These data demonstrate that the

Q200R mutant is less cooperative than the wild type enzyme
with respect to Fru 6-P binding in the absence of the ac
tivator Fru 2,6-P2 . The Q200E mutant has only a slight
cooperativity in the presence of 10-fold higher Fru 6-P
concent rat ion.
The Fru 6-P saturation curves for the wild type en
zyme and the three mutants {Figure 30-33) reveal that Fru
6-P binding is less cooperative after Fru 2, 6-P2 activa
tion than before.

This conclusion is supported by (1)

Hill coefficients close to unity upon activation by Fru
2,6-P2 and (2) small L-values upon activation by Fru 2,6P2

According to the MWC model (Monod et al., 1965), the

shape of the rapidly rising part of a sigmoidal saturation
curve is dependent on the L-value.

The larger the L-val-

ue, the greater the sigmoidicity of the curve.

When the

L-value is small, there is only slight sigmoidicity, hence
little cooperativity.

Thus, the small L-values seen after

Fru 2,6-P2 activation indicate that the cooperativity of
Fru 6-P binding is small in the presence of Fru 2,6-P2.

Ill

Goodness-of-fit values were used to evaluate
curve-fitting to the two types of curves.

It is notewor

thy that, although cooperativity of Fru 6-P binding de
creases, the saturation curves in the presence of Fru 2,6P2 fit better to the cooperative (MWC-based) curve
to the rectangular hyperbolic curve.

than

This is true for the

wild type enzyme and the Q200E and Q200A mutants.

The

Q200R mutant data, however, fit to the rectangular hyper
bolic equation slightly better than to the cooperative
curve. Furthermore, the Vmax and Km values for the wild
type enzyme and the three mutants indicate that the rect
angular hyperbolic curve also fits validly to the data for
each enzyme in the presence of Fru 2,6-P2 * Despite the
goodness-of-fit values and the values for Vmax and Km men
tioned above, the Hill coefficients and the L-values as
well as visual inspection indicate that the cooperativity
of Fru 6-P binding to the wild type enzyme and the three
mutants decreases after activation by Fru 2,6-P2 In the presence of citrate, the KR value and the L
value for the wild type enzyme and for the Q200R mutant
show that the cooperative curve is probably not a good fit
to the data for these two enzymes.

This is because satu

ration by Fru 6-P is not achieved in the presence of
citrate.

The Vmax value and the Km value for the wild

type enzyme also Indicate that the rectangular hyperbolic
curve fits poorly to the data of the enzyme.
In summary, comparisons of the goodness-of-fit, the
Kr values calculated from the cooperative curve, and the
Hill coefficients indicate that the wild type enzyme data
fit to the cooperative curve better than the Q200R mutant
data do in the absence of activator Fru 2,6-P2 . A compar
ison of the L-values and the Hill coefficients before and
after activation by Fru 2,6-P2 demonstrates that Fru 6-F
binding to all the enzymes analyzed is less cooperative
upon Fru 2,6-P2 activation.

CHAPTER FOUR
DISCUSSION

4.1

Sequence Diversity In the 5' Untranslated Region
of RMPFK cDNA*

The results of the characterization of two full-length
RMPFK cDNAs described in Section 3.1.3 show the sequence
diversity in the 5" untranslated region of these cDNAs.
Comparision with the upstream genomic sequence (courtesy of
Dr. Z. Chen) indicates that cDNA-A (corresponding to cDNA
65) is formed by

a splicing event which removes a 1.7 Kb

intron located upstream of the ATG codon while cDNA-B (cor
responding to cDNA 13) retains at least the 3'-region of
this intron.

A comparison of the 5' untranslated regions

of the two RMPFK cDNAs with those of the three HMPFK cDNAs
(Figure 34) reveals that all five cDNAs share the same
splicing acceptor sites located 8 bp 5' of ATG codon.
However, sequences upstream of the splicing junction are
different.

Thus far, only one 5' exon has been found in

each of these five cDNAs. These observations suggest
strongly that transcription of both rabbit and human muscle
PFK genes starts at multiple sites, and splicing subse
quently takes place between a downstream splicing donor
site and the common splicing acceptor site 8 bp upstream of
the ATG codon.
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rigure 34.
Comparison of the 5' untranslatad regions of
two BHPFX cDNAs and thraa human muscle P1K cDNAs.
(A) The
complete exon/intron organization of rabbit muscle PFK
gene. Solid boxes, coding exon I through XXII; open boxes.
upstream untranslated sequences; downward arrows, potential
splicing donor sites; upward arrows, potential splicing ac
ceptor sites; open triangles. SP1 sites; solid triangles.
MyoD sites; open diamond, muscle specific enhancer. The
1.7 Kb intron in cDNA-A (corresponding to cDNA 65) is indi
cated by the downward bent line. The open box with a
broken end indicates an untranslated region, the 5' end of
which in not known. In cDNA-B (corresponding to cDNA 13)
the 3' end of the upstream intron, hatched box, is contigu
ous to Exon I of RMPFK gene.
(B) Three human muscle PFK
cDNAs (Nakajima et al., 1990). The dashed line and box in
dicate an intron with unknown length and 5' untranslated
sequence.
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4.1.1.

Structural features In the promoter region
of RMPFK gene

A 500 bp GC rich region (67 %) located in the up
stream sequence of RMPFK gene contains 50 CpG sites (Bird/
1987) . As shown in Figure 34, various cis-elements exist
in the promoter region of this gene: three SP1 binding
sites (Roth et al., 1985), five MyoD binding sites (Aviv
and Ledar, 1972), and one muscle specific enhancer (Deng
and Wu, 1983).

These elements may work coordinately with

ubiquitous as well as muscle-specific transcription factors
to assemble a transcription initiation complex.

The

TATAAAA sequence is found to exist in the untranslated re
gion of cDNA-A.

The transcription of this sequence casts

doubt on the function of the TATA box in this gene.

This

problem has been resolved recently (see below).
More recently, colleagues in our laboratory have
identified multiple transcription start sites for RMPFK
gene by using primer extension method coupled with anchored
polymerase chain reaction (Xiao, et al., manuscript in
preparation).

Sequences of the amplified DMA products have

shown that transcription of this gene starts from a major
site 27 bases downstream of the TATA box and from two sites
which are TATA independent.

This result indicates that the

TATA box does indeed govern the major initiation event of
the RMPFK gene transcription.

The transcripts that begin

at the two TATA-independent transcription sites are
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consistent with the sequences of RMPFK cDNA-A (#65) and B
(#13), respectively, reported in this dissertation.

4.2

Expression and Purification of Recombinant
RMPrK

Rabbit muscle PFK has been

expressed at a signifi

cant level in E. coli DF1020 cells by using the plasmid
pPL2 as expression vector (Section 3.2).

The recombinant

enzyme was purified to homogeneity by affinity and anion
exchange chromatography.

The purified enzyme is essential

ly identical to PFK isolated from rabbit skeletal muscle
with respect to SDS-polyacrylamide gel electrophoresis
mobility, Western blot patterns, and kinetic properties.
Several attempts have been made to use other E. coll
expression systems, including the T7 promoter system and
the tac promoter system, to express RMPFK.

The major prob

lem with using these systems is that the endogenous E. coll
PFK activity contributes to that of the recombinant RMPFK
to an undetermined extent, complicating the results during
purification.

Since the E. coli host DF1020 is deficient

in EcPFK-1, we chose a pPL2/DF1020 system for the expres
sion of recombinant RMPFK. With this system, PFK activity
can be directly detected by growth of cells containing re
combinant RMPFK on selective agar plates using mannitol as
carbon source. This expression system has three advantages
over other expression systems.

First, DF1020 cells give a
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higher level of RMPFK expression than other E. coli
strains.

Second, growth on mannitol plates provides a vis

ible selection for clones which express RMPFK.

Third, E.

coli PFK activity has been excluded in this system.
The availability of purified recombinant RMPFK
provides the opportunity for a thorough kinetic study of
the structure/function relationships of this enzyme.

Dif

ferent strategies have been employed to purify the cloned
RMPFK.

The addition of 0.5 mM ATP and protein inhibitor in

the column buffer solves the problem of losing enzyme ac
tivity during the purification steps.

The combination of

<NH4)2S04 precipitation, affinity chromatography and anion
exchange chromatography provides us with a protocol to
purify this cloned enzyme in four days and to have a high
yield (49%) of pure enzyme.
Although the pPL2/DF1020 is not a super-expression
system (the yield of the recombinant protein is no more
than 30% of the total cellular protein) for RMPFK, it pro
vides a sufficient level of expression.

Approximately 1 mg

of purified RMPFK can be obtained from 5 liters of cell
culture.

This scale is suitable for the enzymological

studies reported here.

We believe that the level of ex

pression of RMPFK in bacterial host can be improved.

There

are 18 AGG/AGA arginine codons in RMPFK cDNA (Lee, et al.,
1987)

These arginine codons are rarely used in E. coll

cells (Wada et al., 1991).

It would improve the expression
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of RMPFK in E. coli to use site-directed mutagenesis to
change AGG/AGA codons into other arginine codons which are
abundant in E. coli genes.

Alternatively, introduction of

a vector encoding an aginine tRNA (AGG/AGA) gene into a E.
coll host would serve the same purpose (Brinkmann et al.,
1989) .

4.3

Site-Directed Mutagenesis

To probe the structure and function of RMPFK, we have
applied the method of site-directed mutagenesis on the cDNA
of this enzyme.

Glutamine 200 was replaced with alanine,

arginine, asparagine and glutamate.

The mutated enzymes

were purified to homogeneity by affinity and anion exchange
chromatography.
One widely applied method of site-directed mutagene
sis is that developed by Kunkel (1985).

Theoretically,

Kunkel's method is an efficient way to construct mutants.
In practice, however, this method involves the tedious pro
cedure of screening for mutation, and has rather low yield
(30%) of mutants.

This low yield of mutants is assumed to

be due to such factors as incomplete in vitro polymeriza
tion, primer displacement by the DNA-polymerase
used in the fill-in reaction, and the repair of the unmethylated DNA strand (Kramer, et al., 1984).
The commercial "Altered Sites in vitro Mutagenesis
System" has adventages over Kunkel's method in two
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important aspects: 1) The use of ampicillin selection for
the mutation yields a high percentage (85 %) of mutants,
and 2) the use of a special repair oligonucleotide
eliminates the need for screening large numbers of colonies
by hybridization.

Two additional features of this system

are the use of the repair-minus E. coli strain BMH71-18 mut
S and the use of T4 DNA polymerase.

The BMH71-18 mut S

strain supresses in vivo mismatch repair (Zell and Fritz,
1987).

It is used in the first round of transformation,

thus minimizing the chance of repairing the amber codon
mismatch in the ampicillin resistant gene and the mutagenic
mismatch in the cloned gene.

T4 DNA polymerase is used in

the synthesis reaction in place of Klenow fragment because
the former does not displace the strand (Nossal, 1974) and
therefore preserves the mutagenic oligonucleotide.

4.4

Mutation of Gln-200 to Arginina, Alanine or
Glutamate

The chief aim of this study has been to investigate
the structural role of Gln-200 in RMPFK during the R-T
transition.

The data presented in Section 3.3. demonstrate

that mutations of Gln-200 (which is located in the hypo
thetic 6-F loop of RMPFK) affect the enzyme's kinetics dra
matically.

The residue at position 200 of RMPFK has been

substituted with amino acids having charged side chains or
a smaller uncharged side chain.

Mutation of Gln-200 to
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arginine causes an elevation in affinity for Fru 6-P along
with a reduced cooperativity of Fru 6-P binding.

Mutation

to alanine or glutamate results in a drastic reduction of
activity of the enzyme under the same conditions.

The

condition used for analyzing the allosteric properties of
RMPFK PFK

in these studies was 7 mM ATP, which is required

for the maximum activity of the Q200R mutant at pH 7.0.
The MWC model (Monod et al., 1965) is used in this discus
sion as the conceptual framework for understanding
allosteric properties of the wild type and the mutants
RMPFK, although the truth is undoubtedly more complex than
this simple two-state model (see Section 3.3.3).
The kinetic properties of the Q200R mutant suggest
that changing the Gin at position 200 to a positively
charged residue causes the enzyme to have an R state-like
conformation.

The SQ 5 ^pru g_p) of this mutant is 4-fold

less than that of wild type RMPFK.

The cooperativity of

this mutant for Fru 6-P binding decreases (n ■ 1.9, com
pared to 2.4 for wild type RMPFK). The substitution of
Gln-200 with Arg seems to stabilize the R-state conforma
tion.
The kinetics of the Q200A mutant with respect to
[Fru 6-PI suggest that it has a quaternary structure simi
lar to the inactive, T state structure.

This mutant can

not achieve half-saturation at pH 7.0 in the absence of Fru
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2,6-P2* even with a concentration of Fru 6-P over 200 mM.
However, it does achieve half-saturation at low concentra
tion of Fru 6-P in the presence of activator, Fru 2,6-P2 at
pH 7.0, or at pH 8.0,
The mutation of Gln-200 to a negatively charged resi
due, glutamate, may lead to a perturbation of the Fru 6-P
binding site of RMPFK.

The Sg,5 (pru g_pj of mutant Q200E

is much greater than that of wild type.

Moreover, the

Q200E mutant has higher sensitivity to citrate inhibition.
In spite of their extremely low activities at high
concentration of Fru 6-P, mutants Q200A and Q200E can be
activated by Fru 2,6-P2 to reach the wild type activity
level.

These results suggest that glutamine at position

200 is not involved in the binding of Fru 2,6-P2 .
In BsPFK, the structural changes at the substrate
binding site during the T to R transition result in an
interaction between Arg-162 and phosphate of Fru 6-P.
Concomitantly, Glu-161 switchs out of the substrate binding
cleft (Schirmer and Evans, 1990). The x-ray crystal
structure of BsPFK in the R state shows that Glu-161 forms
an indirect interaction with residue His-39 (P. R. Evans,
personal communication). A proposed H39:E161 ion pair may
stabilize the R-state conformation of BsPFK.

A description

of the possible interactions between residue 39 and 161 or

their equivalents in different species is presented in
Table 8. Glu-53 in RMPFK is equivalent to His 39 in BsPFK.
BsPFK is the only one to have both a basic residue at posi
tion 39 and an acidic one at position 161.

This H39:E161

interaction is consistent with a hyperbolic kinetic profile
of BsPFK with respect to Fru 6-P (Valdez et al., 1989).
The putative interaction between His-39 and Glu-161 may
play a major role in stabilizing the R state conformation.
In RMPFK, the residue at position 200 (corresponding
to Glu-161 in BsPFK) is glutamine, and residue at position
53 (corresponding to His-39 in BsPFK) is glutamate.

The

Q200R mutation may give the enzyme a more R state like con
formation, while the Q200A and the Q200E mutations may give
the enzyme a more T state like conformation.

These results

are consistant with predicted interaction between Gln-200
and Glu-53 in RMPFK.

Mutation at Glu-53 has to be conduct

ed to determine whether or not an interaction between Gln200 and Glu-53 is important for stabilizing the R state
conformation.
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Table 8.
The possible interaction between residues #39 4 #161 in
different PVK species
Residue #
PFK Species
Mammal N-half
Yeast N-half
Mammal C-half
Yeast C-half (A/B)
E. coli
B. stearothermophilus

39

161

E
E
D
N
D
H

Q
S
K
R/G
Q
E

The residues presented for yeast and mammalian PFK's are
those in positions corresponding to residues #39 and #161
of the bacterial enzymes. (P. R. Evans's personal communi
cation)

CHAPTER FIVE
SUMMARY

Two full-length cDNAs of RMPFK have been purified
and characterized.

The sequence evidence shows that the

two cDNAs are identical in their coding region but are
different in their 5'-untranslated region, a result sug
gesting multiple promoters and transcription start sites
in the gene of RMPFK.
The coding region of RMPFK cDNA has been cloned in
several expression vectors, including pET-3c which uses a
T7 phage promoter, and pPL2 which is controlled by the PL
promoter of lambda phage.

The latter vector was chosen

for the expression of RMPFK in E. coli host DF1020.

This

system provides a visible selection for clones which pro
duce RMPFK and it is free of endogenous PFK activity.

Re

combinant RMPFK has been purified and shown to resemble
the PFK purified from rabbit muscle with respect to physi
cal and enzymatic properties.
On the basis of amino acid sequence similarity be
tween RMPFK and BsPFK and the crystal structure of the
latter, the glutamine residue at position 200 of RMPFK has
been substituted by arginine (Q200R), alanine (Q200A) and
glutamate (Q200E). Under the conditions of pH 7.0 and 7
mM ATP, the Q200R mutant has a 4-fold lower Sq 5 (pru 6-P)
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than the wild type RMPFK, the Q200A mutant is essentially
inactive, and the Q200E mutant has an activity lower than
that of the wild type RMPFK, even at much higher concen
trations of Fru 6-P.

The cooperativity of Fru 6-P

binding, as measured empirically by the Hill coefficient,
is lower for the Q200R mutant and for the Q200E mutant
than for the wild type RMPFK,

The recombinant RMPFK and

the three mutants are all activated by Fru 2,6-P2 .

ABBREVIATIONS

BSA

- Bovine serum albumin

BsPFK

- Bacillus stearothermophilus PFK

C-type PFK

- Brain isozyme of PFK

cAMP

- 3', 5'-cyclic AMP

cDNA

- Complementary DNA (transcribed or copied
from mRNA)

ddA

- Dideoxy ATP

ddC

- Dideoxy CTP

DMSO

- Dimethylsulfoxide

DTT

- Dithiothreitol

EcPFK-1

- Major EcPFK

EcPFK

- Escherichia coli PFK

EDTA

- Ethylenediaminetetraacetic acid

Fru 1,6-P2

- Fructose 1,6-bisphosphate

Fru 2,6-P2

- Fructose 2,6-bisphosphate

Fru 6-P

- Fructose 6-phosphate

HLPFK

- Human liver PFK

HMPFK

- Human muscle PFK

hr

- hour

Km

- Michaelis constant

Kb

- Kilobase pairs

LB

- Luria-Bertani

L-type PFK

- Liver isozyme of PFK
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MLPFK

- Mouse liver PFK

M-type PFK

-

NAD

- Nicotinamide adenine dinucleotide

NADH2

- Nicotinamide adenine dinucleotide

Muscle isozyme of PFK

(reduced)
nt

- Nucleotide

PAGE

- Polyacrylamide gel electrophoresis

PEG

- Polyethylene glycol

PFK

- 6-Fhosphofructo-l-kinase

Pi

- Inorganic phosphate

PMSF

- Phenylmethylsulfonyl fluoride

Q200A

- Gln-200 to Ala mutant

Q200E

- Gln-200 to Glu mutant

Q200N

- Gln-200 to Asn mutant

Q200R

-

RF

- Replicative form

RMPFK

- Rabbit muscle PFK

Sq ^

- Half-saturation concentration

SDS

- Sodium dodecylsulfate

SDS-PAGE

- SDS polyacrylamide gel electrophoresis

TAE

- Tris-Acetate EDTA buffer

TBE

- Tris-Borate EDTA buffer

TCA

- Tricarboxylic acid cycle

TEMED

- N, N. N', N'-tetramethylethylenediamine

Tris.HCl

- Tris(hydroxymethyl) aminomethane chloride

YT

- Yeast/Tryptone

Gln-200 to Arg
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Appendix Z
Aliganut of DMA ■•quwiota of rabbit muscle PFK cDNA13 (top) and cDNA-65 (bottom) in tha coding ragion
and tha 3' untranslatad ragion.
Alignment was started from the ATG codon to the 3'
untranslated region.
1 ATGAC CCATGAAGAGCACCATGCAGCCAGAACCCTGGGGGTCGGCAAGGC 50
^8914^^^4990429655
1 ATGACCCATGAAGAGCACCATGCAGC CAGAACCCTGGGGGTCGGCAAGGC 50
51 CATCGCGGTGCTCACCTCCGGCGGAGATGCCCAAGGTATGAATGCTGCCG 100
548636832822981^^^
51 CATCGCGGTGCTCACCTCCGGCGGAGATGCCCAAGGTATGAATGCTGCCG 100
*

•

*

*

*

101 TCCGGGCTGTGGTTCGAGTTGGCATCTTCACTGGTGCCCGGGTCTTCTTC 150

llltlllllllllllfllllllllllllllllllllllllllljllllll

101 TCCGGGCTGTGGTTGCAGTTGGCATCTTCACTGGTGCCCGGGTCTTCTTC 150
■

•

•

»

•

1 51 GTCCATGAGGGCTACCAGGGCCTGGTGGATGGCGGGGACCACATCCGGGA 200

II IIIIIIIIII II II IIIII IIIIIIII II IIIIIIIIIII II IIIIII

151 GTCCATGAGGGCTACCAGGGCCTGGTGGATGGCGGGGACCACATCCGGGA 2 0 0
201 GGCCACGTGGGAGAGCGTCTCCATGATGCTGCAGCTGGGAGGCACCGTGA 250

llllllllllllllllllllllllllllllllllllllllllllllllll

2 0 1 GGCCACGTGGGAGAGCGTCTCCATGATGCTGCAGCTGGGAGGCACCGTGA 250
2 51 TTGGAAGTGCTCGGTGCAAGGACTTCCGGGAGCGAGAGGGACGTCTCCGA 300
^^8011809543295095
2 51 TTGGAAGTGCTCGGTGCAAGGACTTCCGGGAGCGAGAGGGACGTCTCCGA 300
3 01 GCCGCCCACAACCTGGTGAAGCGTGGGATCACCAATCTGTGTGTGATAGG 350

llllllllllllllllllllllllllllllllllllllllllllllllll

301 GCCGCCCACAACCTGGTGAAGCGTGGGATCACCAATCTGTGTGTGATAGG 350
351 CGGTGATGGCAGCCTCACTGGGGCTGATACCTTCCGTTCTGAGTGGAGCG 400

llllllllllllllllllllllllllllllllllllllllllllllllll

3 51 CGGTGATGGCAGCCTCACTGGGGCTGATACCTTCCGTTCTGAGTGGAGCG 400
•

*

*

«

•

401 ACCTGTTGAGTGACCTCCAGAAAGCGGGTAAGATCACAGCCGAGGAGGCC 4 5 0

j 1 1 1 1 1 n i j f i f 1 1 1 1 1 1 1 1 1 1 1 m 11

4 0 1 ACCTGTTGAGTGACCTCCAGAAAGCGGGTAAGATCACAGCCGAGGAGGCC 450
451 ACGAGGTCCAGCTACCTGAACATCGTGGGCCTGGTCGGCTCCATTGACAA 500

llllllllllllllllllllllllllllllllllllllllllllllllll

4 5 1 ACGAGGTCCAGCTACCTGAACATCGTGGGCCTGGTCGGCTCCATTGACAA 500
5 0 1 TGACTTCTGCGGTACGGATATGACCATCGGCACCGACTCTGCCCTGCACC 550

IIIIIIIIIIIIIIIIIIIIIIIIIIIIIUIIIIIIIIIIIIIIIIIII

5 0 1 TGACTTCTGCGGTACGGATATGACCATCGGCACCGACTCTGCCCTGCACC 5 5 0
551 OGATCACAGAGATTGTGGATGCCATCACCACCACTGCCCAGAGCCACCAG 600
196452958^73821^^^
5 5 1 GGATCACAGAGATTGTGGATGCCATCACCACCACTGCCCAGAGCCACCAG 600
6 0 1 AGGACATTTGTGTTAGAAGTGATGGGCCGCCACTGTGGATACCTGGCCCT 6 5 0

llllllllllllllllllllllllllllllllilllllllllllllllll

6 0 1 AGGACATTTGTGTTAGAAGTGATGGGCCGCCACTGTGGATACCTGGCCCT 6 5 0

134

651 GGTCACCTCTCTGTCCTGC GGTGCTGACTGGGTCTTCATTCC TGAGTGTC 700

I1IIIIIIIIIIItIIIIIIIIIIIIIIIIIIIIIItIIIIIIIIIIIII

651 GGTCAC CTC TCTGTC CTGCGGTGCTGACTGGGTCTTCATTC CTGAGTGTC 700
•

•

*

i

«

701 CTCCGGATGACAACTGGGAGGATCACCTGTGTCGCCGGCTCAGTGAGACA 750

IIIIIIIIIIIIIIIIIIIIIIII1IIIIIIIItIIIIIfIIIIIIIIII

701 CTCCGGATGACAACTGGGAGGATCACCTGTGTCGC CGGCTCAGTGAGACA 750
751 CGGACCCGTGGCTCTCGCCTCAACATCATCATTGTGGCCGAGGGTGCAAT 800

I I I I I I I I I I I I I I I I I I I I I I ! I I I I II I I I I I I I I I I I I 1 I I I I I I I I

751 CGGACCCGTGGCTCTCGCCTCAACATCATCATTGTGGCCGAGGGTGCAAT 800
801 CGACAGGAACGGGAAACCGATCACCTCAGAAGGCGTCAAGGATCTGGTGG 850
262909681308
.....
801 CGACAGGAACGGGAAACCGATCAC CTCAGAAGGCGTCAAGGATCTGGTGG 850

IIIIIIIIIIIIIIN
*

•

*

•

»

851 TGAAGCGTCTGGGCTATGACACGCGGGTCACCGTCCTGGGGCATGTGCAG 9 0 0

I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 11 I I I t I I I I I I I

851 TGAAGCGTCTGGGCTATGACACGCGGGTCACCGTCCTGGGGCATGTGCAG 9 0 0
901 CGAGGTGGAACCCCCTCAGCCTTCGACAGGATCCTGGGCAGCAGGATGGG 950

lilllimilMlllllllllllllllllllllllllllllllllllll

901 CGAGGTGGAACCCCCTCAGCCTTCGACAGGATCCTGGGCAGCAGGATGGG 950
*

*

*

♦

•

951 CGTGGAAGCAGTGATGGC GCTGTTGGAGGGGAC CCCGGACACCCCGGCCT 1000

I I I I I I I I I I I I I I I I I I I I I fj I I I I I I I I I I I I I I f I I I ! I I I I I I I I

951 CGTGGAAGCAGTGATGGC GCTGTTGGAGGGGAC CCCGGACACCCCGGCCT 1000
1001 GTGTGGTGAGCCTGTCTGGTAACCAGGCCGTGCGCCTGCCGCTCATGGAA 1050

IIIIIIIIIIIII1IIIIIIItI!II!IIIIIIItIIIIIIIIIIIIIII

1001 GTGTGGTGAGCCTGTCTGGTAACCAGGCCGTGCGCCTGCCGCTCATGGAA 1 0 5 0
1051 TGTGTCCAGGTGACCAAAGATGTGACCAAGGCCATGGACGAGAAGAGATT 1 1 0 0

I I I I I I i I I I I I I I I I I I I I I 1 I 1 I I I i I I Ii I I I fl I I I I I I I I I I II I

1051 TGTGTCCAGGTGACCAAAGATGTGACCAAGGCCATGGACGAGAAGAGATT 1 1 0 0
1101 TGATGAAGCCATGAAGCTGAGAGGCCGGAGCTTCATGAACAACTGGGAGG 1150

I I I I I I I I I I I II I I I I I I I If I I I I I I I I t I I I I I I I I I I I I ( I I I I I I

1101 TGATGAAGCCATGAAGCTGAGAGGCCGGAGCTTCATGAACAACTGGGAGG 1 1 5 0
1151 TGTACAAGCTTCTGGCTCACATCAGACCCCCAGCCCCCAAGAGTGGCTCG 1 2 0 0

I II II I I I I I I I I II I II I I I I I I II II I I I I M i l I I I M i l I I I I I I I

1151 TGTACAAGCTTCTSGCTCACATCAGAC CCCCAGC CCCCAAGAGTGGCTCG 1200
1201 TACAC CGTAGCTGTGATGAAC GTGGGTGCC CCGGCGGCAGGCATGAATGC 1250

llllllllllllllllllllllllllllllllllllllllllllllllll

1201 TACACCGTAGCTGTGATGAACGTGGGTGCCCCGGCGGCAGGCATGAATGC 1250
*

•

i

*

I

1251 AGCTGTTCGCTCCACTGTGAGGATTGGCCTGATCCAGGGCAACCGGGTGC 1300

llllllllllllllllllllllllllllllllllllllllllllllllll

1251 AGCTGTTCGCTCCACTGTGAGGATTGGCCTGATCCAGGGCAACCGGGTGC 1 3 0 0
1 3 0 1 TGGTGGTGCAC GATGGCTTCGAGGGGCCTGC CAAGGGCCAGATTGAGGAA 1 3 5 0

lllllllllllllllllllllllllllllllllllllltlllllllllll

,.A

1 3 0 1 TGGTGGTGCACGATGGCTTCGAGGGGCCTGC CAAGGGCCAGATTGAGGAA 1 3 5 0
1 3 5 1 GCCGGCTGGAGCTACGTAGGGGGCTGGACCGGGCAAGGCGGCTCCAAACT 1 4 0 0

lllllllllllllllllllllllllllllfllllllllllllllllllll

1 3 5 1 GCCGGCTGGAGCTACGTAGGGGGCTGGACCGGGCAAGGCGGCTCCAAACT 1 4 0 0

1 4 0 1 GGGCACTAAAAGGACTCTACCCAAAAAGAGCTTCGAACAGATCAGTGC CA 1 4 5 0

IIIIIIIIII II II IIfIIIt IIIIIIIII| II | | | | | | I| | | | | | | I | |

1401 GGGCACTAAAAGGACTCTACCCAAAAAGAGCTTCGAACAGATCAGTGCCA 14 50
1 4 5 1 ACATAAC CAAGTTTAACATCCAGGGC CTGGTCATCATTGGGGGCTTTGAG 1500

lllllllllllllllllllllllllinnilllllllltllltlfllll

1451 ACATAAC CAAGTTTAACATC CAGGGCCTGGTCATCATTGGGGGCTTTGAG 1500
•

*,

■

■

a

1501 GCTTACACCGGGGGCCTGGAGCTGATGGAGGGCAGGAAGCAGTTTGACGA 1550

1111111111111111111 i1111111111111 f1111111111111111

1501 GCTTACACCGGGGGCCTGGAGCTGATGGAGGGCAGGAAGCAGTTTGACGA 1550
1551 GCTCTGCATCCCTTTCGTGGTCATCCCTGCCACAGTCTCCAACAACGTTC 1600

llllllllllllllllllllllllllllllllllllllllllllllllll

1551 GCTCTGCATCCCTTTCGTGGTCATCCCTGCCACAGTCTCCAACAACGTTC 1600
1601 CCGGCTCAGACTTCAGCGTCGGGGCGGACACGGCGCTCAACACCATCTGC 1650

IIIiIIIIIIIII1IIItIIIIIIIII|IIIIIIIIIII|1IIIIIIIII

1601 CCGGCTCAGACTTCAGCGTC GGGGCGGACACGGCGCTCAACACCATCTGC 1 6 5 0
1651 ACGACGTGTGAC CGTATCAAGCAGTC CGCAGCGGGCACCAAGCGCCGGGT 1 7 0 0

IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIjIIIIIIIIIIIII

1 6 5 1 ACGACGTGTGACCGTATCAAGCAGTCCGCAGCGGGCACCAAGCGCCGGGT 1700
1701 GTTCATCATCGAGACCATGGGCGGCTACTGCGGCTACCTGGCCACCATGG 1750
^^6652525449955794
1701 GTTCATCATCGAGACCATGGGCGGCTACTGCGGCTACCTGGCCACCATGG 1750
1751 CAGGACTGGCAGCCGGGGCCGATGCTGCCTACATTTTTGAGGAGCCCTTC 1 8 0 0

llllllllllllllllllllllllllllllllllllllllllllllllll

1751 CAGGACTGGCAGCCGGGGCCGATGCTGCCTACATTTTTGAGGAGCCCTTC 1 8 0 0
1 8 0 1 ACCATCCGAGACCTGCAGGCGAATGTTGAACACCTGGTGCAAAAGATGAA 1850

lllllllllllllllllllllllllf llllllllllillllll lllllll

1801 ACCATCCGAGACCTGCAGGCGAATGTTGAACACCTGGTGCAAAAGATGAA 1850
1851 GACGACTGTGAAGAGAGGCTTGGTGCTGAGGAACGAGAAGTGCAATGAGA 1900

III II IIII II II II II II III II III IIII II III IIIIIIII II II II

1851 GACGACTGTGAAGAGAGGCTTGGTGCTGAGGAACGAGAAGTGCAATGAGA 1900
1 9 0 1 ATTACACCACGGACTTCATCTTCAACCTGTACTCTGAGGAGGGGAACGGC 1950

II II I I I I I l l l l II II II I I I I I II I I I I II II I II I I I l l l l I I I I II

1901 ATTACACCACGGACTTCATCTTCAACCTGTACTCTGAGGAGGGGAAGGGC 1 9 5 0
1951 ATCTTCGACAGCAGGAAGAACGTGCTTGGCCACATGCAGCAGGGCGGGAG 2 0 0 0

llllllllllllllllllllllllllllllllllllllllllllllllll

1 9 5 1 ATCTTCGACAGCAGGAAGAACGTGCTTGGCCACATGCAGCAGGGCGGGAG 2 0 0 0
2 0 0 1 CCCCACTCCCTTTGACAGGAACTTTGCTACTAAGATGGGAGCCAAGGCCA 2 0 5 0

i m i m m i i m m i i i i i i i i i m m i i i i i i i i i i i i i i i i

2 0 0 1 CCCCACTCCCTTTGACAGGAACTTTGCTACTAAGATGGGAGCCAAGGCCA 2 0 5 0
2 0 5 1 TGAACTGGATGGCTGGGAAGATCAAGGAGAGTTACCGCAACGGGCGGATC 2 1 0 0

Ifllllllllllllllllllllllllllllllllllllllllllllllll

2 0 5 1 TGAACTGGATGGCTGGGAAGATCAAGGAGAGTTACCGCAACGGGCGGATC 2 1 0 0
2 1 0 1 TTCGCCAACACCCCTGACTCCGGCTGTGTTCTGGGAATGCGTAAGAGGGC 2150

tlllllllllllllllllllllllllllllllllllllllllllllllll

2 1 0 1 TTCGCCAACACCCCTGACTCCGGCTGTGTTCTGGGAATGCGTAAGAGGGC 2150

2 1S 1 TCTGGTCTTCCAACCAGTGACTGAGCTGCAGAATCAGACGGACTTTGAGC 2 2 0 0

1111 f11111111111111111111111111111111!11111111111 i

2 1 5 1 TCTGGTCTTCCAACCAGTGACTGAGCTGCAGAATCAGACGGACTTTGAGC 2 2 0 0
2 2 0 1 ACCGAATCCC CAAGGAACAGTGGTGGCTGAAGCTGCGGCCCATCCTCAAA 2 2 5 0

tIIIIIIIIII1IiIIItIItIIII!IIIIIIIIIIIIIIIiIII|IiI|

2 2 0 1 ACCGAATC CC CAAGGAACAGTGGTGGCTGAAGCTGC GGCCCATC CTCAAA 2 2 5 0
2 2 5 1 ATCCTAGCCAAGTACGAGATTGACTTGGACACCTCCGAGCACGCGCATCT 2 3 0 0

I I II I I I I I I I I I I I I I t I I II I I I I I I I I I I I I t I t I I I I I I I I II I I I

2 2 5 1 ATCCTAGCCAAGTACGAGATTGACTTGGACACCTCCGAGCACGCGCATCT 2 3 0 0
2 3 0 1 GGAGCACATCTC CCGGAAGCGGTCTGGGGAAGCCACCGTCTAAGCCTCGG 2 3 5 0

IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII

2 3 0 1 GGAGCACATCTCCCGGAAGCGGTCTGGGGAAGCCACCGTCTAAGCCTCGG 2 3 5 0
2 351 AGCGAGGGACAGGCTGTCTGATCACATCAAAGATGCACGCCGTGTCCATG 2 4 0 0

IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII!IIIIIIIIIIIII

2 351 AGCGAGGGACAGGCTGTCTGATCACATCAAAGATGCACGCCGTGTCCATG 2 4 0 0
2 4 0 1 TCGTAGCTCTTTAGTCATTAGGGTCCCTGTACTTGTGCACCCAAGGCCGT 24 50

llllllllllllllllllllllllllllllllllllllllllllllllll

2 4 0 1 TCGTAGCTCTTTAGTCATTAGGGTCCCTGTACTTGTGCACCCAAGGCCGT 2 4 5 0
2 4 5 1 GACCAGCTCTGGCCGGGAACCGGGAGCATGCAGTAGGTGGAAGCTCCTGT 2 5 0 0

IIIIIIIIIIIIIIIIIIIIIII(II IIIIIIIIIIIII IIIIIIII IM

24 51 GACCAGCTCTGGCCGGGAACCGGGAGCATGCAGTAGGTGGAAGCTCCTGT 2 5 0 0
2 5 0 1 AGTAGACTCGGTCATGACCCGCACCCCAGCCTGGTCTGTTACACAGGCAG 2 5 5 0

I I I I I I I I I I I I I I I I I I I I II I I I I I II I I I I I I I I I I I I I I I I I I I I I

2 5 0 1 AGTAGACTCGGTCATGACC CGCACCCCAGCCTGGTCTGTTACACAGGCAG 2 5 5 0
*

•

*

#

•

2 5 5 1 GGTCCTGTAGTGCTCCTGCTGGACCACACAGGTAGAACTCCCTTTACACG 2 6 0 0

IIIIIIIIIIIIIIIIIIIIIIIIItIIIIIIIIIIIIIIIIIIIIIIII

2 5 5 1 GGTCCTGTAGTCCTCCTGCTGGACCACACAGGTAGAACTCCCTTTACACG 2 6 0 0
«

•

•

»

t

2 6 0 1 CGCTTTATTTATTTCTTTGTGTTAACAAGAGTGTCGGCTTCTCACACTCC 2 6 5 0

III

2 6 0 1 CGC........................................................................................................................

2603

Appendix II
Sequences ot Synthetic Oligonucleotides

A.

Linkers for subcloning

Code

Sequence (S' to 3')

pET-Xba
CTAGCAATAATTTTGTTTAACTTTAAGAAGGAGTCTAGACCCGGGGGTAC
pET-Kpn

CCCCGGGTCTAGACTCCTTCTTAAAGTTAAACAAAATTATTG

PL2-Cla

CGATTAAGGAGGTCTAGACTGATATCGGTACCCAGC

PL2-Sac

GGGTACCGATATCAGTCTAGACCTCCTTAAT

B.

Primers for in vitro mutagenesis and DNA sequencing

Code

Sequence (S' to 3')

Start Position
(nt)

PFK1X

ATGACCCATGAAGAGCACCATGC

PFK1XC

GGCTGCATGGTGCTCTTCATGGGTC

PFK2

Remarks

1

sequencing primer

27

sequencing primer

TCCGAGCCGCCCACAAC

298

sequencing primer

PFK3

AATGACTTCTGCGGTAC

499

sequencing primer

PFK4

TGTCCTCCGGATGACAAC

697

sequencing primer

PFK6

GCCATCCAGTTCAT

1061

sequencing primer

PFK7

CTGGAGCACATCTCCCG

2298

sequencing primer

Ala200

GCCCAGAGCCACGCGAGG
ACATTTGTG

586

138

make Gln-200 to
Ala mutant

Arg200

AGAGCCACCGGAGGACATTTG

Glu200

AGAGCCACGAGAGGACATTTG

591 make Gln-200 to
Arg mutant
591 make Gln-200 to
Glu mutant

Appendix III
Amino Acid smqumnce of the recombinant PMPI7C
This amino acid sequence was generated from the
Sequence Analysis Software Package of the Genetic
Computer Group (GCG) (University of Wisconsin
Biotechnology Center).

1

HTHEEHHAAR TLGVGKAIAV LTSGGOAQGH

n aa vrav v rv

G lF T G A R vrr

51

VHEGYQGX.VD GGDHZREATW ESVSMHLQLG GTVIGSARCK DFREREGRLR

101

AAHNLVKRGI TNLCVIGGDG SLTGAOTFRS EWSDLLSDLQ KAGKZTAEEA

151

TRSSYLNIVG tVGSIDNDFC GTDHTIGTDS ALHRZTEZVD AITTTAQSHQ

201

RTFVLEVWGR HCGYLALVTS LSCGADWVFZ PECPPDDNWE OHLCRRLSET

251

RTRGSRLNII IVAEGAIDRN GICPITSEGVK DLWKRLGYD TRVTVLGHVQ

301

RGGTPSAFDR ILGSRHGVEA VHA1XBGTPD TPACWSLSG NQAVRLPLME

351

CVQVTKDVTK AHOEKRFOEA HKLRGRSFMN NWEVYKLLAH IRPPAPKSGS

401

YTVAVMNVGA PAAGMNAAVR STVRIGLIQG NRVLWKDGF EGPAKGQIEE

45 1

AGWSYVGGWT GQGGSKLGTK RTLPKKSFEQ ISAWITKFNI QGLVIIGGFE

501

AYTGGLELME GRKQFDELCI p rw iP A T V S NHVPGSOFSV GADTALNTIC

55 1

TTCDRIKQSA AGTKRRVFII ETMGGYCGYL ATHAGLAAGA DAAYIFEEPF

601

TIRDLQAHVE KLVQKMKTTV KRGLVLRNE1C CNEWYTTDF1 FNLYSEEGXG

651

IFDSRKNVLG HHQQGGSPTP FDRNFATKMG AKAHNWHAGK IKESYRNGR1

70 1

FANTPDSGCV LGHRKRALVF QPVTELQNQT DFEHR1PKEQ WWLKLRPILX

751

ILAKYEIDLD TSEHAHLEHI SRXRSGEATV *

140

Appendix IV
Restriction Cutting Sites end DMA Sequence of the Coding
Region of The rull Length RMFFK cDNA
This cDNA map was generated from the Sequence
Analysis Software Package of the Genetic Computer Group
(GCG) (University of Wisconsin Biotechnology Center).
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CGOTACCTGCTCTTCTCTAAACTACTTC GGTACTTCGACTCTCCGGCCTCGAAGTACTTG
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TC CAC TGTGAG GATTGGCC TGAT CCAGGGCAAC CGGGTGCTGGTGGTGCACGATGGCTTC
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Appendix V
Coroon Solutions/Reagents

LB (Luria-Bertani) Medium:
Per litter:
Bacto-tryptone
Bacto-yeast extract
NaCl
Adjust pH to 7.5

10 g
5 g
10 g

2 x YT Medium:
Per litter:
Bacto-tryptone
Bacto-yeast extract
NaCl
Adjust pH to 7.5

16 g
10 g
10 g

NZY Medium:
Per litter:
NaCl
MgSO^.7H20
Yeast extract
NZ Amine

5
2
5
10

M9 Medium:
10 x M9 Salt: 500 ml
Na2HP04
30
15
k h 2p o 4
n h 4ci
5
2.5
NaCl
Mix CaCl2, MgS04, glucose, thiamine
H20 just before use.
TYP Medium:
Per litter:
Bacto-tryptone
Bacto-yeast extract
NaCl
k 2h p o 4

16
16
5
2.5

SM Buffer:
Per litter:
NaCl
MgS04
Tris-Cl (pH 7.5)

g
g
g
g

g
g
g
g
and 1 x M9 salt with

g
g
g
g

5.8 g
2 g

50 ml of 1 M stock
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20 x SSC:
Per litter:
NaCl
sodium citrate
Adjust pH to 7.0

175.3 g
88.2 g

20 x SSPE
3.6 M NaCl
200 mM NaH2P04 (pH 7.4)
20 mM EDTA (pH 7.4)
50 x Denhardt's Solution:
500 ml:
Ficoll
5 g
Polyvinylpyrrolidone
5 g
BSA
5 g
Filter through a Nalgene filter.
Dispense into 50 ml aliquots and store at -20°C.
Prewashing Solution:
50 mM Tris-Cl (pH 8.0)
1 M NaCl
1 mM EDTA
0.1 % SDS
Prehybridization Solution:
50 % foramide
5 x Denhardt's solution
5 x SSPE
0.1 % SDS
100 fig/ml denatured, salmon sperm DNA
TE (Tris-EDTA):
10 mM Tris-Cl (pH 8.0)
1 mM EDTA
50 x TAE (Tris-Acetate-EDTA):
Per litter:
Tris base
glacial acetic acid
0.5 M EDTA

242 g
57.1 ml
100 ml

5 x TBE (Tris-Borate):
Per litter:
Tris base
Boric acid
0.5 M EDTA

54 g
27.5 g
20 ml
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Lysozyme Solution (Solution I):
50 mM glucose
10 mM EDTA
25 mM Tris-Cl (pH 8.0)
4 mg/ml lysozyme
Add powdered lysozyme to the solution just before use,
Solution II:
0.2 N NaOH
1 % SDS
3 M Potassium Acetate, pH 4.8 (Solution III):
To 60 ml of 5 M potassium acetate add 11.5 ml of glacial
acetic acid and 28.5 ml H20. The resulting solution is
3 M with respect to acetate.
Phage Precipitation solution:
3.75 M ammonium acetate, pH 7.5
20 % polyethylene glycol (MW 8,000)
% Sequencing gel:
Per 500 ml:
71.2
40 % acrylamide
75
2 % bis-acrylamide
urea
230
50
5 x TBE
Filter through 3MM Whatman filter paper
brown bottle.

ml
ml
g
ml
and store in a

Competent Cells Solutions:
RF1:
Per litter:
RbCl
12 g
MnCl2 .4H20
9.9 g
potassium acetate (pH 7.5)
30 ml of a 1 M stock
1.5 g
CaCl2 .2H20
150 g
Glycerol
Adjust the pH to 5.8 with 0.2 M acetic acid. Sterilize
by filtration through a pre-rinsed 0.22 pm membrane.
RF2:
Per litter:
MOPS (pH 6.8)
RbCl
CaC12.2H20
Glycerol

20 ml
1.2
11
150

of a 0.5 M stock
g
g
g

Adjust pH to final pH 6.8 with NaOH and sterilize by
filtration through a pre-rinsed 0.22 pm membrane.

Laemmll Solutions (for SDS separating ael):
30 % aerylamide/0.8 % bisacrylamide
Per 200 ml:
Aerylamide
60 g
N',N-methylene-bisacrylamide
1.6 g
Filter through a 3 MM Waterman paper and store at
a brown bottle.
4 x Stacking Gel Buffer, pH 6.8 {0.5 M Tris-Cl)
Per 100 ml:
Tris Base
6.05 g
Adjust pH to 6.8 with 1 N HC1.
4 x Running Gel buffer, pH 8.8 (1.5 M Tris-Cl)
Per 500 ml:
Tris Base
91 g
Adjust pH to 8.8 with 1 N HC1.
2 x SDS/sample buffer:
Tris base
glycerol
SDS
2-mecaptoethanol
Bromophenol Blue
Adjust to pH 6.8.

0.76 g
10 ml
1g
1 ml
0.5 mg

SDS Running Tank buffer, pH 8.3:
Tris base
glycine
SDS
Adjust volume to 4 litters.

12 g
57.6 g
4g

Western Blotting Solutions:
Transfer Buffer:
Tris base
glycine
bulk methanol
Adjust volume to 5 litters

12.1 g
56.33 g
l1

Tris/Saline Buffer (pH 7.4) :
Tris base
NaCl

2.42 g
18 g

Tris/Saline with BSA
BSA
Tris/Saline

9g
300 ml

Tris/Saline with NP 40
NP 40
Tris/Saline

0.3 ml
600 ml
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Test Sera:
12®I Staph A, about 30,000,000 cpm.
Radlolodinatlon solutions:

0.01 M Phosphate, pH 7.4.
0.1 M phosphate, pH 7.2.
Nal (125):
50 mci/ml in 0.05 N NaOH
1 % BSA:
BSA (fraction V)
0.01 M phosphate

1g
100 ml

10 % Trichloroacetic acid
Test Dye
Blue Dextran
Phenol red
0.01 M phosphate

10 mg
10 mg
100 ml

Chloramine-T
40 mg in 10 ml 0.1 M phosphate.
Sodium Metabisulfite
50 mg in 20 ml 0.1 M phosphate.
1 % sodium iodide
100 mg in 10 ml 0.1 M phosphate.
Protein Purification Solutions:

Sonication Buffer, pH 8.0:
50 mM Tris-phosphate, 25 mM NaF, 0.1 mM EDTA, 0.5 mM
ATP,10 mM DTT and 0.1 mM PMSF (0.5 M stock solution in ab
solute ethanol).
Column Buffer, pH 6.0:
50 mM Tris-phosphate, 25 mM NaF, 0.1 mM EDTA, 0.1 mM
ATP, ImM DTT and 0.1 mM PMSF.

Appendix VI
cDNA Cloning
A.

Amplification of the Lambda EAPXI Vactor library
This protocol was followed as described by Maniatis et

al. (1982) with minor modifications.
1.

A liquid culture of the

XLl-Blue cells

started from a single colony

was

and grown overnight

with vigorous shaking at 37°C in LB media
supplemented with 0.2 % maltose and 10 mM MgSO^.
2.

The cells were spun at 1000 x g and adjusted to an
a600 * °*5 *

3.

Mix aliquots of the packaged lambda amplified
suspension containing approximately 50,000
recombinant bacteriophage with 600 Jil of XLl-Blue
cells in 2059 Falcon tubes.

4.

Incubate tubes containing phage and XLl-Blue cells
15 minutes at 37°C.

5.

Mix Each aliquot of infected bacteria with 6.5 ml
of melted 48°C top agarose and poured evenly onto a
1-2 day old NZY 150 mm plate of bottom agar.

The

plates were incubated at 37°c for 9 hours.
6.

Pipette 10 ml of SM buffer onto each plate, the
plates were incubated at 4°C overnight with
vigorous shaking.
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7.

The bacteriophage suspension was recovered from
each plate and pooled into a sterile polypropylene
tube.

Chloroform was added to 5 % into each

tube.
8.

Remove Cell debris by centrifugation for 5 min at
4000 x g.

9.

Recover the supernatant, pool and transfer to a
sterile polypropylene tube.
% and store in

10.

Add Chloroform to 3

aliquots at 4°C.

The titer of the amplified library was
approximately 10 11 pfu/ml.

cDNA screening
1.

Approximately 50,000 plaques were plated with 600
p.1 Of Agpg = 0.5 XLl-Blue cells and 6.5 ml of
top agarose on a large 150 mm NZY plate.

Twenty

plates were used to screen 1 x 106 plaques.
2.

The plates were incubated at 37°C for 9 hours and
then chilled 4 hours at 4°C.

Transfer Plaques

for 2 minutes onto nitrocellulose filters labeled
(waterproof ink). Duplicate filter were used for
each plate,

The second transfer last for 4

minutes.
3.

Nitrocellulose filters

left from plates were

submerged in 1.5 M NaCl, 0.5 M NaOH for 2 minutes
and neutralized 5 minutes by submerging in 1.5 M
NaCl, 0.5 M Tris-HCl, pH 8.0.
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4.

Rinse Filters for 30 seconds in o.2 M Tris-HCl, pH
7.5, 2 x SSC.

5.

Blot filters dry on Whatman 3MM
and baked at 80°C for 2 hours.

filter paper
Store the master

plates wrapped with parafilm at 4°C to use for
subsequent phage isolation.
6.

Submerge the baked filters in 6 x SSC for 5
minutes.

7

Transfer the filters to a flat-bottomed plastic
box containing 300 ml prewashing solution and
incubate at 42°C for 2 hours.

8.

Pour off the prewashing solution.

Incubate the

filters for 4 hours at 42°C in 100 ml

9.

prehybridization solution.
Denature the 32P-labeled probe DNA by heating to
100°C for 5 minutes.

Add the denatured probe to

the prehybridization solution covering the
filters. Incubate at 42°C for 24 hours.
10.

After the hybridization is completed, discard the
hybridization solution.

Wash the filters 3-4 times

for 5-10 minutes each wash, in 500 ml of 2 x SSC
and 0.1 % SDS at room temperature.
11.

Wash the filters twice for 1 hour in 500 ml of a
solution of 1 x SSC and 0.1 % SDS at 68°C.

12.

Dry the filters in air at room temperature.

Tape

the filters onto sheets of used X-ray film and

place pieces of tape marked with radioactive ink
at several locations on the used X-ray film.
13. Cover the filters in Saran Wrap and apply to X-ray
film (Kodak XR) and exposed 50 hours at -70°C.
14.

After development, align the film with the filters
using the marked left by the radioactive ink.
Identify the positive plaque by aligning the dots
on the tracing paper with those on the agarose
plate.

15. Use a sterile Pasteur pipette to pick up each
positive plaque and place into 1 ml of SM
containing a droplet of chloroform.

This phage

stock is stable for up to a year at 4°C.
C. In vivo excision
This protocol was provided by Stratagene (La Jolla, CA)
1.

In a 50ml conical tube combine:
a.

200 Hiof ODgQQ * 1.0 XLl-Blue cells.

b.

200 illof Lambda ZAPII phage stock

(containing >

1 x 10^) phage particles.
c. 1 fil of R408 helper phage (1 x 1011 pfu/ml) .
Incubate mixture at 37°C for 15 minutes.
2.

Add 5 (il of 2 x YT media and incubate 3 hours at
37°C with shaking.
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3.

Heat tube at 70°C for 20 minutes, then spin tube
for 5 minutes at 4000 x g.

4.

Decant the supernatant into a sterile tube.

5.

To plate the rescued phagemid,

combine the

following in two 15 ml tubes:
a. 10 |il of phage stock and 200 ml A^ qq = 1.0
XLl-Blue

host cells.

b. 20 jil of a 10~2 dilution of phage stock from
step 5 above and 200(11 A600 - 1.0 of XLl-Blue
host cells.
6.

Incubate tubes at 37°C for 15 min.

Plate 1 to 100 (ll on LB/ampicillin plates and
incubate overnight at 37°C.

7.

Colonies appearing on the plate contain the
pBluescript double stranded phagemid with the
cloned DNA insert. Streak the colony on a new
LB/amp plate.

Appendix VII
Isolation of Plasmid DNA
These protocols were adapted from Maniatis et al., (1982)
with minor modification.
A.

Large-seaIs preparation by CsCl centrifugation:
1.

Inoculate 3 ml of LB medium containing the
appropriate antibiotic with a single bacterial
colony and grow for 8 hours.

2.

Transfer 2.5 ml of the cell culture to 250 ml LB
medium containing the appropriate antibiotic.
Incubate at 37°C

with vigorous shaking until

a 600 reaches approximately 0.6, then add 1.25 ml
of chloramphenicol (34 mg/ml in ethanol).
Incubate at 37°C for 12-16 hours.
3.

Harvest the bacterial cells by centrifugation at
6000 x g for 10 minutes at 4°C.

4.

Resuspend the bacterial pellet in 5 ml of solution
I, transfer the solution to a 35 ml tube and let
stand at room temperature for 5 minutes.

5.

Add 10 ml of freshly made solution II. Cover the
top of the tube with parafilm and mix
contents by gently
times.

6.

the

inverting the tube several

Let stand on ice 10 minutes.

Add 7.5 ml of an ice-cold

solution of solution III

and let tube stand on ice 10 minutes.
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7.

Centrifuge on a Sorvall roter at 20,000 rpm for
30 minutes at 4°C.

8.

Transfer equal volume of the supernatant into each
of two 30 ml Corex tubes.

9.

Add 0.6 volume of isopropanol to each tube.

Mix

well and let stand at room temperature for 15
minutes.
10. Recover the DNA by centrifugation in a Sorvall
roter at

10,000 rpm for 30 minutes at room

temperature.
11. Discard the supernatant.

Wash the pellet with 70

% ethanol at room temperature, then dry the DNA
pellet briefly in vacuum desiccator.
12. Dissolve the pellet in a total volume of 4 ml of
TE.
13. For every ml of DNA solution add exactly 1 g of
solid cesium chloride.
14. Add 0.8 ml of a solution ethidium bromide (10
mg/ml in

I^O) for every 10 ml of cesium chloride

solution.

Mix well.

The final density should be

1.55 g/ml.
15. Transfer the CsCl solution to a clear
ultracentrifugation tube and fill the remainder of
the tube with light paraffin oil.
16. Centrifuge in a Beckman Type-65 roter at 45,000
rpm for 20 hours.

17. Remove the cap from the tube.

Collect the lower

band of DNA into a orange cap tube through a #18
needle inserted into the side of the tube.
18.

Remove the ethidium bromide by adding equal volume
of 1-butanol saturated with water.
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19.

Centrifuge at

x g for 3 minutes at room temperature.

Transfer the lower aqueous phase to a clean tube.
Repeat the extraction 4-6 times until all the
pink color disappear from the aqueous solution.

20.

Dialyze the aqueous phase against 3 changes of TE.

Mini-preparation procedure:
1.

Pour 1,5 ml of overnight cell
eppendorf tube.
temperature.

2.

culture into an

Centrifuge for 2 minutes at room

Drain the supernatant.

Resuspend the pellet in 100 jil of ice-cold
solution I and let stand at room temperature for
5 mins.

3.

Add 200 p.1 of solution II.

Mix the contents in

the tube by inverting the tube several times.
Let stand on ice for 5 minutes.
4.

Add 150 Hi of solution III.

Mix the contents in

the tube by inverting the tube sharply several
times.
5.

Let stand on ice for 5 minutes.

Centrifuge at 4°C for 5 minutes and transfer the
supernatant to a fresh tube.

Add 0.5 ml of phenol/chloroform (1:1), vortex and
let stand for 2 minutes.

Centrifuge at room

temperature for 5 minutes and transfer the
supernatant to a fresh tube.
Add 1 ml of ethanol and let stand at room
temperature for 5 minutes, then centrifuge at
room temperature for 5 minutes.
Hash the pellet with 1 ml of 70 % ethanol and
centrifuge

at room temperature for 5 minutes.

Remove ethanol and dry the pellet briefly by
vacuum.
Dissolve the DNA pellet in 10 |Al of TE (pH 8.0)
Use 5 ill for each digestion reaction.

Appendix VIII
DMA Fragment* Subcloning
A.

Isolation of tba DNA fragment form low melting

agarose gel
This is a protocol provided by the Geneclean Kit
with minor modification.
1.

Digest interested DNA and the cloning vector with
appropriate restriction enzymes, then inactivated
the enzymes by heating at 70°C for 10 minutes,

2.

Prepare 0.8 - 0.6 % low melting agarose gel in 50
mM Tris-acetate (TAE) buffer.

3.

Load the digested samples onto the gel.

The

target DNA fragment can be visualized under long
wavelength UV light by staining the gel with 0.5
t*g/ml of ethidium bromide for 20 minutes after
gel electrophoresis.
4.

Excise the DNA fragment from the gel and incubate
the gel slice at 45°C to 55°C for 5 minutes.

5.

Add 2.5 x volume of Nal stock solution, mix the
contents in the tube and further incubate the
tube at 45°C to 55°C for 3 minutes.

6.

Add 5 ill of Glassmilk suspension, vortex and place
on ice for 5 minutes.

7.

Pellet Glassmilk/DNA complex for 5 seconds.
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8.

Wash pellet 3 times with New solution.

Add 500

|il of ice-cold New solution to the pellet for each
wash.
9.

Spin the

tubefor a few seconds and remove the

last bitof liquid with
10.

a pipette tip.

Elute DNA into 10 |il of H20.

Incubate the tube at

45°C to 55°C for 3 minutes.
11.

Centrifuge for 30 seconds to make a solid pellet
and carefully transfer the supernatant containing
the eluted

B.

DNA to a fresh tube.

Ligation reaction
insert DNA

x(11 (molar rate of vector:insert*l:5)

vector DNA

yHi

10 x ligation 2 |ll
buffer
T4 DNA ligase 1 U
H20 to 20 Hi
The reaction mixture is incubated at room
temperature for 4 hours.
C.

Preparation of Proxen Competent Celia
The protocol described here is similar to that

described by Hanahan (1983).
1.

Inoculate a fresh single colony into 2 ml LB
medium and grow for overnight.
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2.

Transfer 0.25 ml of overnight cell culture to 25
ml of SOB medium in a 500 ml Erlenmeyer flask.

3.

Incubate at 37°C with moderate agitation until the
cell density is O*D.gg0 = 0.4 - 0.5.

4.

Collect the culture into 50 ml polypropylene
centrifuge tube and chill on ice for 15 minutes.

5.

Pellet the cells by centrifugation at 3000 r.p.m.
in a clinical centrifuge for 15 minutes at 4°C.
Drain the pelleted cells thoroughly by inverting
the tube on paper towels, and rapping to remove
any liquid.

6.

Resuspend the cell pellet by moderate vortexing 8
ml of RF1.
minutes.

7.

Incubate the cells on ice for 15

Pellet cells as in step 5.

Resuspend the cells in 2 ml of RF2.

Incubate the

cells on ice for 15 minutes.
8.

Distribute 200 pi

aliquots into chilled

microcentrifuge tubes.
9.

Freeze in a solid C02/alcohol bath, then place at
-70°C.

D.

Transformation procedure

This protocol is similar to the procedure of using
frozen competent cells described by Hanahan (1983).
1.

Mix 200 JjLI of competent cells with 3 Hi
ligation reaction into chilled eppendorf tube

by moving pipette tip through cells while
dispensing; then gently tap tube to mix.
Incubate cells on ice for 30 - 60 minutes.
Heat shock at 42°C for 90 seconds.

Place tube

on ice.
Add 0.8 ml of room temperature LB medium and
shake at 225 r.p.m. for 1 hour at 37°C.
Plate on LB or 2 x YT plates containing the
appropriate antibiotics.
overnight at 37°C.

Incubate plate

Appendix IX
ExoXII/Mung Bean Nuclease Deletions
These protocols were followed as described in Stratagene
manual.
A.

Digestion of clones of interest
1.

Use CsCl purified double-stranded DNA.

2.

Double digest clones to completion with a
unique 3' overhang restriction site and a
unique 5# or blunt restriction site that must
lie between the insert and the 3' site chosen.

3.

Check for completion of first digestion on an
agarose gel.

B.

ExoIII/Hung Delations
1.

A stop solution is prepared for each ExoIII time
point.

Dilute 20 Jil of 10 x Mung Bean Buffer

into 155 M-l of H2O in an eppendorf tube for each
time interval desired.
2.

The reaction is started by adding 20 U of ExoIII
for each 1 ^ig DNA.

Incubate reaction at 30°C

(delete 230 bp/minute) and remove 25 Jil aliquots
from the reaction mixture at the appropriate time
intervals.

Add the 25 |il aliquot directly to a

tube containing the 175 jil aliquots of diluted
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Mung Bean Nuclease Buffer prepared before
starting the ExoIII reactions and place on dry
ice.
For each time point the reaction contains:
double-digested DNA

5 pg

2 x Exo buffer

12.5 pi

fresh 100 mM p-mecaptoethanol

2.5 pi

Exonuclease III

20 U

H20 to 25 pi
When all the aliquots have been removed, heat
tubes at 68°C for 15 minutes, and then place on ice.
Add 15 U of Mung Bean Nuclease to each time point
tube

and incubate for 30 minutes at 30°C.

Add:
1 M Tris-Cl, pH 9.5

10 Ml

0 M LiCl

20 Ml

20 % SDS

4 Ml

phenol:chloroform

250 Ml

Vortex, spin 1 minute in microfuge, remove upper
aqueous layer and extract the upper layer with
chloroform.
Add 25pi 3 M sodium acetate, pH 7.0 to the
aqueous phase.

8.

Add 0.65 ml of cold ethanol.

Chill on dry ice 10

mins and spin in a microfuge for 20 minutes.
9.

Drain off the supernatant and wash the pellets
with 80 %

ethanol.

Dry the pellet,

10.

Redissolve DNA pellet in 15 pi of TE.

11.

Ligate DNA deletions using the following
conditions:
ExoIII/Mung treated DNA

1 pi

10 x ligation buffer

2 pi

5 mM ATP, pH 7. 0-7.5

2 pi

T4 DNA ligase

2 pi

H20 to 20 p.1
12. Seven pi of the remaining 14 pi of ExoIII/Mung
treated DNA is used for gel electrophoresis
analysis.
13. Use 1 pi of the ligation reaction to transform 200
pi of JM109 competent cells.
Quick screen of CxoIII/Mung transformants
1.

Isolate 3-4 colonies from each time interval with
sterile toothpick and streak each as a single line
onto LB/amp plates.

2.

Grow overnight at 37°C.

Scrape bacteria with sterile toothpick and
resuspend in 40 |il of 1 x STE
Add 40 pi of phenol:chloroform and vortex.
Microfuge 1 minute.
Transfer supernatant to eppendorf tube and add 1
pi of RNaseA (1 mg/ml).
Wait 2 minutes.

Load 20 pi onto 1 % agarose gel

and electrophoresis to compare supercoiled Exo/Mung
deleted plasmids.

Appendix X.
Sequencing Double Stranded end Single Stranded DNA Using
Sequenase Kit
A.

Clean up and denaturation of plasmid DNA
This is a protocol provided by personal

communication from Dr. Lo.
1.

Add 6 |ll of RNaseA (10 mg/ml) to 5 |ig of DNA in
300 |ll of low TE buffer and incubate at 37°C for
30 minutes.

2.

Add 3 |ll of Proteinase K and 15 |ll of 10 % SDS
into the tube and incubate at 37°C for further 30
mins.

3.

Extract with phenol/chloroform twice.

Transfer

the aqueous phase to a fresh tube.
4.

Add 150 |ll of 7.5 M NH4OAc (pH 7.5) and 900 |ll of
ice-cold ethanol.

5.

Incubate on ice for 30 minutes.

Microcentrifuge at 4°C for 10 minutes.

Dry the

pellet by vacuum.
6.

Redissolve the pellet in 64 |il of low TE (pH 8.0).

7.

Add 16 |il of 5 x denaturing buffer (0.4 g NaOH +
20 ml 0.5 M EDTA pH 8.0, in 10 ml H20), mix and
incubate at room temperature for 5 minutes.
Transfer to ice.
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8.

Add 15 ml 2 M NH4OAc {pH 4.5) and 220 *11 ethanol,
mix and let stand in -70°C freezer for 30 minutes.

9.

Centrifuge the DNA tube at 12,000 r.p.m.20 mins at
4°C

10.

Wash the pellet with 70 % ethanol and recentrifuge
for 10 minutes.

11.

Vacuum dry the pellet and use immediately or store
at -20°C as dry pellet.

B.

Single stranded DMA preparation

a)

Preparation of Ml3 single stranded DNA template
1.

Inoculate a single colony of DH5aFf into 2 ml 2 x
YT medium and grow overnight at 37°C.

2.

Transfer 30 jil of overnight cell culture to 3 ml
2 x YT and add 5 nl of phage stock to infect the
cells.

3.

Grow cells at 37°C for 5 hours.

Transfer 1.5 ml of the cell culture to an
eppendorf tube and centrifuge for 5 minutes.

4.

Pour the supernatant to a fresh eppendorf tube and
add 200 Hi of 20 % PEG/2.5 M NaCl.

5.

Vortex the supernatant well and let stand at room
temperature for 30 minutes.

6.

Centrifuge the tube and remove supernatant
completely.
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7.

Resuspend the phage pellets and combine two tubes
in 100 Hi TE.

8.

Add 100 p.! of TE (pH 8.0) saturated phenol, vortex
well, and let stand at room temperature for 2
minutes.

9.

Transfer the aqueous phase to a fresh eppendorf
tube, add 1/10 volume of NaOAc (2.5 M) 2.5 volume
ethanol, and precipitate at -70°C for 30 minutes.

10.

Centrifuge at 4°C for 15 minutes and pour out the
supernatant.

Wash the pellet with 70 % ethanol and

vacuum dry.
11. Dissolve the pellet in 20 H1 of TE <PH 8.0).
12. Load 3 Hi onto a 0.8 % agarose gel.

Check the

purity and concentration by comparing to the M13
ssDNA provided by Sequenase kit.
b)

Isolation of single stranded DNA from cells

containing phagemids
This is a protocol provided by Stratagene for
rescuing ssDNA with minor modifications.
1.

Grow an overnight culture containing phagemid DNA
in XLl-Blue or JM109.

2.

Transfer 0.3 ml of cell culture to 3

ml TYP medium

and shake at 37°C in a sterile 50 ml conical tube.

Add R408 helper phage during log phase (OD600 *
0.3) at a multiplicity of infection of 20:1 (phage
to cells). Continue shaking for 8 hours.
Transfer the culture to an eppendorf tube.

Spin

down cells for 1-2 minutes in a microfuge, 11,000
x g, room temperature.
Transfer 1.2 ml of the supernatant to a fresh
eppendorf tube and add 300 M-l of a 3.5 M NH40Ac
(pH 7.5)/20 % PEG solution. Invert to mix, and let
stand at room temperature for 15 minutes.
Spin the tube for 20 minutes at 11,000 x g in
microfuge.

Thoroughly remove the supernatant.

Spin again for 1 minute and remove any remaining
supernatant.
Resuspend the pellet in 300 )il TE (pH 8.0).

Add

300p.1 buffer-saturated phenol/chloroform, vortex
for 1 minute, and spin for 1 minute in microfuge.
Remove

the top aqueous phase and transfer to a

fresh tube.

Repeat the extraction until there is

no interface left.

Add 300 )il chloroform, vortex

for 1 minute and spin for 2 minutes.
aqueous phase to a fresh tube.

Transfer the

Precipitate the ssDNA by adding 200 ill 7.5 M
NH^OAc and 800 jil of cold ethanol.

Leave on ice

for 15 mln. Spin for 20 minutes# 11,000 x g, 4°C.
Drain the supernatant and carefully wash the
pellet with 80 % ethanol.

Vacuum dry and dissolve

the pellet in 20 jil TE
Analyze ssDNA on a 0.8 % agarose gel.
Preparation of a 6 % sequencing gel
Clean the glass plates well and siliconize the
inner side of small glass plate the previous day
of gel electrophoresis.
Wash away the remaining siliconizing solution with
distill water and let it air dry.
Wipe the glass plates with 95 % ethanol.

Place

the spacers and arrange the glass plates, clamp on
two long sides.
Degas 80 ml 6 % gel mix for

20

minutesat room

temperature.

10

%

Add 234 Hi Of

ammonium

persulfate and 21 pi TEMED to initiate the
polymerization reaction.
Mix the gel solution well and pour it between
the glass plates.

Put the 0.4 mm comb in place.

Let it polymerize for 5-40 minutes.
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E.

Dideoxy sequencing reaction
This step-by-step protocol is provided by USB for

DNA sequencing with Sequenase.
1.

Primer annealing
for each reaction mix:
5 x sequenase buffer

2 nl

ssDNA template 1 |ig ( 5 |ig dsDNA) x ill
primer

y ill

H20 to 10 |xl
Mix and incubate at 65°C for 30 minutes, and
gradually cool at room temperature to < 35°C.
During this cooling time,
1) Label G, A, T, C tubes.

Aliquot 2.5 ill of the

dideoxy termination mixes into these tubes,
before use, warm up to 37°C.
2) Dilute the labeling mix 1 : 5 by double distilled
water.
3) Measure 8 Jll Sequenase dilution buffer and keep
on ice.

Add 1 111 sequenase and mix just before

use.
4) Take the

dATP out of freezer and warm it

inside fumehood for about 20 minutes.

5) Prerun the gel at 1500 volts 20 mAmp for 15
minutes. This will help wash urea and warm up
the gel.
2.

Labeling and Termination
Add to the primer annealed DNA

10 Hi

Diluted labeling mix

2 |il

0.1 M DTT

1 nl

35S dATP (10 HCi)

0.5 Hi

Incubate at room temperature for 2-3 minutes.
Aliquot 3.5 H* of the labeling reaction to each
of the Gf A, T, C termination tubes and incubate
at 37°C for 5 minutes.
to each tube.

Keep

Add 4 h *

stop solution

the tubes on ice.

Running, fixing, drying and exposure of the gel
1.

Heat the tubes at 95°C for 3 minutes and keep on
ice.

2.

Wash the wells with 0.5 x TBE before loading the
sample.

Load 3 H1 Per well; load one set of G,

A, T, c samples at a time.
3.

Stop the running of the gel when the fast dye
reaches the bottom of the gel.

4.

Cool the gel for 10 minutes and remove the small
glass plate.

Fix the gel in 1 litter of 10 % acetic acid and 12
% methanol for 30 minutes and siphon out the
fixing solution.
Put a Piece of 3MM Waterman paper onto the gel and
gently take out the gel from the glass plate Cover
it with Saran wrap.
Place in drier and dry it at 80°C for 40 minutes.
After complete drying, remove Saran wrap and
expose to Kodak X-OMAT AR film at room
temperature overnight.

Jtppwtdix XI.
Radioiodination of Protains with Chloramina-T
Preparation of Sephadex G-25
To prepare enough Sephadex for 10 columns (10
iodinations), weigh about 20 g of dry Sephadex into
a 250 ml beaker.
Slowly add about 100 ml 0.01 M phosphate. Gently
swirl the resin to remove large pockets of air.
The gel requires at least 3 hours at room
temperature to swell completely.
Rinse the resin by carefully decanting the
original buffer after the resin has settled for
about 1 hour and replacing it with fresh buffer.
This should be repeated at least twice.

The final

ratio of buffer to resin should be about 1.5.
Store the swollen resin at 4°C.
Preparation of Sephadex G-25 gel filtration column
The column consists of a 10 ml glass disposable

\

pipette.
Affix a short (about 1 cm) piece of thin
Tygon/tubing to the tip of the pipette.
Cut the tip off an 18 gauge needle, then cut a 1.5
cm length from the same needle.

Slip the needle

with base onto the outlet of the stopcock, then
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attach about 12 inches of Tygon tubing.
Fit the second piece of needle to the tubing.
4.
C.

Plug the bottom of the pipette with glass wool.

Radioiodination of proteins
To perform the reaction: All the following steps

should be done in a fumehood on ice.
1.

Add 0.5 or 1 mCi Nal (125) to the protein
sample.

2.

To initiate the reaction, add 20 p.1 of the
Chloramine-T solution and mix well.

3.

Time the reaction for 3 minutes.

4.

To terminate the reaction, add 100 p.1 of the
sodium metabisulfate solution and mix well.

5.

In order to minimize noncovalent binding of
1-125 to proteins, add 200 p.1 of carrier sodium
iodide solution and mix well.

D.

Gal filtration of the radiolabeled protein
1.

Open the stop cock on the column and allow the
buffer to just reach the top of the packed bed.
Very gently apply the reaction mixture to the top
of the column bed and allow it to soak
completely into the column bed before adding more
0.01 M phosphate to elute the column.

2.

As soon as the reaction mixture is applied to the
column, begin collecting fractions —

15 drops or

about 0.3 ml per fraction.

Collect at least 40

fractions before stopping the column and closing the
stopcock.
Count 5 pi aliquots of each fraction in the auto
gamma counter.

Plot the data and pool

appropriate fractions —

iodinated protein should

elute early (12-18 fractions) and free iodine and
other salt elute late (23-40 fractions). Measure
the total activity and volume of the pooled
fractions.
To keep the iodinated proteins from possible
aggregating and falling out of solution, add 10 p.1
of 10% Deoxycholate to the pooled fractions.
Store at -20°C.
Determination of covalently-bound 1-125
Add I0p.l of 1 mg/ml BSA to 5 Hi of the iodinated
protein in an eppendorf tube.

Count this in the

gamma counter.
Add 900 Hi of 10 % TCA that has been chilled and
incubate on ice for 20-30 minutes to facilitate
protein precipitation.
Centrifuge for 10 minutes in the eppendorf
centrifuge 12,000 x g, preferably at 4°C.
Carefully pipette out the supernatant and count
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the pellets in the auto gamma counter.
% TCA precipitability

Calculate

A p p e n d ix X I I

Western Blotting
This procedure was taken directly from W. N. Bur, Ana. Biochem. 112, 195-203, 1901.
Transfer the proteins from a SDS-PAGE to the
nitrocellulose membrane.
Block the membrane in ISO ml Tris/saline with BSA
at 37°C for 30 minutes.
Treat the membrane with the diluted rat anti-PFK
antibody in 60 ml Tris/saline with BSA at room
temperature for 90 minutes.
Remove the test serum by multiple washes as
follows: first, wash for 10 mins with 100 ml
Tris/saline followed by two 20 mins washes with
150 ml Tris/saline with NP 40 and finally for 10
mins in 150 ml saline.
treat the membrane with the

ipe

steph A.

Hash the membrane as step 4.
The treated membrane is briefly blotted dry
between several paper towels and placed in a film
cassette and allowed to expose to a piece of Kodak
XAR-5 x-ray film for 3-18 hours at -70°C.

Appendix XIII
Altered Sites In Vitro Mutagenesis System

A.

Cloning into tha pSCLECT-1 Vactor

B.

Praparation of Phaganid Singla-Strandad DNA
1.

Prepare an overnight culture of cells containing
pSELECT-1 or pSELECT-control phagemid DNA.
(TYP/Tc 15 jig/ml)

2.

Use 1:50 dilution of overnight culture to 5 ml
TYP <Tc 15 lig/ml) .
Shake vigorously at 37° C for 30 min. in a 50 ml
tube.

3.

Add 40 jil of R408 helper phages to the 5 ml
culture. Continue shaking for 6 hours to overnight
with vigorously agitation.

4.

Pellet the cells at 12,000 x g for 15 min. Pour
the supernatant into a fresh tube and spin again for
15 min.

5.

Add 0.25 volume of 3.75 M ammonium acetate
(pH 7.5)/20% PEG. Leave on ice for 30 min.
Centrifuge for 15 min. at 12,000 x g.

6.

Resuspend the pellet in 400 111 of TE and transfer
the sample to a microcentrifuge tube.
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7.

Add 0.4 ml of chloroform:isoamyl alcohol (24:1) to
lyse the phage, vortex for 1 full min., centrifuge
at 12,000 x 9 for 5 min.

8.

Add 0.4 ml of TE-saturated phenol:chloroform to
the aqueous phase, votex for 1 full min. Centrifuge
for 5 min.

9.

Repeat the phenol extraction several times until
there is no visible material at the interface. ('5
times)

10. Add 0.5 volume
+ 2 volumes of
11.

(200 ill) of 7.5 M ammonium acetate
ethanol. Leave at -20°C for 30 min.

Centrifuge at 12,000 x g for 5 min, rinse the
pellet with 70% ethanol. Dry the DNA pellet.

12. Resuspend the DNA in 20 |il of HgO. Estimate the
amount of DNA.

(R408 is 6.4 kb, pSELECT is 5.6 kb)

C.Mutagenesis Procedure
a.

Annealing reaction and mutant strand synthesis
1.

Mutagenesis annealing reaction:

Recombinant pSELECT-1 ssDNA

0.05 pmol

Ampicillin repair oligo (2.2 ng/ml) 1 Jil (o.2 5pmol)
Mutagenic oligo phosphorylated
10X Annealing buffer
H20 to 20 ill

1.25 pmol
2 p.1

Control annealing reaction!
pSELECT-control ssDNA

100 ng {0.05 pmol)

Ampicillin repair oligo

1 |il (0.25 pmol)

lacZ control oligo (10.0 ng/ml)

1 Ml (1.25 pmol)

10X Annealing buffer

2 Ml

H20 to 20 m
2.

Heat the annealing reaction to 70°C for 5 min. and
allow it to cool to roomtemperature.

3.

Place the annealing reaction on iceand

add the

following:
10X synthesis buffer

3 |il

T4 DNA polymerase

1 p.1

T4 DNA ligase

1 pi

H20 to 30 ^1
4.

Incubate the reaction at 37°C for 90 min.

Transformation into 8MH 71-18 mut S
1.

Add 3 Ml of DMSO to 200 Ml of BMH 71-18 mut S
competent cells, mix briefly, and then add the
entire synthesis reaction.

2.

Let the cells sit on ice for 30 min. (Heat shock at
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3. Add 4 ml

of LB broth and incubate at 37°C for 1

hour. (1 ml of the culture can be removed and
spreaded on LB/ampl25 plate)
4.

Add ampicillin to a final concentration of 125 Hg/ml
and incubate at 37°C for 12-14 hours with shaking.

c.

Mlni-prep plasmid DNA

d.

Transformation into JM109
1. Add 3 )il

of DMSO to 200 |il of JM109 competent

cells, mix briefly, and add 100 ng of mutagenized
DNA.
2.

Let the cells sit on ice for 30 min. Heat shock at
42°C for 1-2 min.

3.

Add 2 ml of LB broth and incubate at 37°C for 1
hour.

4.

Divide the culture into two microcentrifuge tubes.

5.

Spread the cells in each tube on an LB/ampl25
plate.
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